Loading...

Razelle Kurzrock

Title(s)Professor, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Balancing clinical evidence in the context of a pandemic. Nat Biotechnol. 2021 Feb 05. Adashek JJ, Kurzrock R. PMID: 33547424.
      View in: PubMed   Mentions:    Fields:    
    2. KRAS-mutated, ER-positive low-grade serous ovarian cancer: Unraveling an exceptional response mystery. Oncologist. 2021 Feb 02. Kato S, McFall T, Takahashi K, Bamel K, Ikeda S, Eskander RN, Plaxe S, Parker B, Stites E, Kurzrock R. PMID: 33528846.
      View in: PubMed   Mentions:    Fields:    
    3. Landscape of Cyclin Pathway Genomic Alterations Across 5,356 Prostate Cancers: Implications for Targeted Therapeutics. Oncologist. 2021 Feb 01. Jardim DL, Millis SZ, Ross JS, Woo MS, Ali SM, Kurzrock R. PMID: 33522043.
      View in: PubMed   Mentions:    Fields:    
    4. Cancer of Unknown Primary in the Molecular Era. Trends Cancer. 2021 Jan 27. Kato S, Alsafar A, Walavalkar V, Hainsworth J, Kurzrock R. PMID: 33516660.
      View in: PubMed   Mentions:    Fields:    
    5. High prevalence of clonal hematopoiesis-type genomic abnormalities in cell-free DNA in invasive gliomas after treatment. Int J Cancer. 2021 Jan 26. Okamura R, Piccioni DE, Boichard A, Lee S, Jimenez RE, Sicklick JK, Kato S, Kurzrock R. PMID: 33497479.
      View in: PubMed   Mentions:    Fields:    
    6. Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics. Clin Cancer Res. 2021 Jan 20. Kato S, Adashek JJ, Shaya J, Okamura R, Jimenez RE, Lee S, Sicklick JK, Kurzrock R. PMID: 33472910.
      View in: PubMed   Mentions:    Fields:    
    7. Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor-based regimens. JCI Insight. 2021 Jan 11; 6(1). Kato S, Okamura R, Adashek JJ, Khalid N, Lee S, Nguyen V, Sicklick JK, Kurzrock R. PMID: 33427211.
      View in: PubMed   Mentions:    Fields:    
    8. Bilateral Postprocedural Rhinitis After Intravenous Sedation With Supplemental Nasal Oxygen (PRAISE SNOG) After Cataract Surgery. Cureus. 2021 Jan 03; 13(1):e12452. PMID: 33552770.
      View in: PubMed   Mentions:
    9. Immune profiling and immunotherapeutic targets in pancreatic cancer. Ann Transl Med. 2021 Jan; 9(2):119. PMID: 33569421.
      View in: PubMed   Mentions:
    10. Relationship between tumor mutational burden and maximum standardized uptake value in 2-[18F]FDG PET (positron emission tomography) scan in cancer patients. EJNMMI Res. 2020 Dec 09; 10(1):150. Haghighat Jahromi A, Barkauskas DA, Zabel M, Goodman AM, Frampton G, Nikanjam M, Hoh CK, Kurzrock R. PMID: 33296034.
      View in: PubMed   Mentions:
    11. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. Blood Adv. 2020 Dec 08; 4(23):6039-6050. van Rhee F, Oksenhendler E, Srkalovic G, Voorhees P, Lim M, Dispenzieri A, Ide M, Parente S, Schey S, Streetly M, Wong R, Wu D, Maillard I, Brandstadter J, Munshi N, Bowne W, Elenitoba-Johnson KS, Fössa A, Lechowicz MJ, Chandrakasan S, Pierson SK, Greenway A, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Chadburn A, Fajgenbaum DC. PMID: 33284946.
      View in: PubMed   Mentions: 1     Fields:    
    12. Standardized uptake value (SUVmax) in 18F-FDG PET/CT is correlated with the total number of main oncogenic anomalies in cancer patients. Cancer Biol Ther. 2020 Nov 01; 21(11):1067-1071. Haghighat Jahromi A, Chang G, Kurzrock R, Hoh CK. PMID: 33131408.
      View in: PubMed   Mentions: 1     Fields:    
    13. The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell. 2020 Oct 14. Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R. PMID: 33125859.
      View in: PubMed   Mentions:    Fields:    
    14. Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. Clin Cancer Res. 2020 Nov 01; 26(21):5579-5587. Janku F, Park H, Call SG, Madwani K, Oki Y, Subbiah V, Hong DS, Naing A, Velez-Bravo VM, Barnes TG, Hagemeister FB, Falchook GS, Karp DD, Wheler JJ, Piha-Paul SA, Garrido-Laguna I, Shpall EJ, Fayad LE, Neelapu SS, Meric-Bernstam F, Kurzrock R, Fanale MA. PMID: 33055173.
      View in: PubMed   Mentions:    Fields:    
    15. Attrition of Patients on a Precision Oncology Trial: Analysis of the I-PREDICT Experience. Oncologist. 2020 11; 25(11):e1803-e1806. Bohan SS, Sicklick JK, Kato S, Okamura R, Miller VA, Leyland-Jones B, Lippman SM, Kurzrock R. PMID: 32949172.
      View in: PubMed   Mentions:    Fields:    
    16. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nat Commun. 2020 10 02; 11(1):4965. Kato S, Kim KH, Lim HJ, Boichard A, Nikanjam M, Weihe E, Kuo DJ, Eskander RN, Goodman A, Galanina N, Fanta PT, Schwab RB, Shatsky R, Plaxe SC, Sharabi A, Stites E, Adashek JJ, Okamura R, Lee S, Lippman SM, Sicklick JK, Kurzrock R. PMID: 33009371.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    17. Survival Implications of the Relationship between Tissue versus Circulating Tumor DNA TP53 Mutations-A Perspective from a Real-World Precision Medicine Cohort. Mol Cancer Ther. 2020 12; 19(12):2612-2620. Rosenberg S, Okamura R, Kato S, Soussi T, Kurzrock R. PMID: 32999047.
      View in: PubMed   Mentions:    Fields:    
    18. From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm. Trends Cancer. 2021 01; 7(1):15-28. Adashek JJ, Subbiah V, Kurzrock R. PMID: 33008795.
      View in: PubMed   Mentions:    Fields:    
    19. Transcriptomics and solid tumors: The next frontier in precision cancer medicine. Semin Cancer Biol. 2020 Sep 17. Tsimberidou AM, Fountzilas E, Bleris L, Kurzrock R. PMID: 32950605.
      View in: PubMed   Mentions:    Fields:    
    20. Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients. Mol Oncol. 2021 Jan; 15(1):67-79. Charo LM, Eskander RN, Okamura R, Patel SP, Nikanjam M, Lanman RB, Piccioni DE, Kato S, McHale MT, Kurzrock R. PMID: 32881280.
      View in: PubMed   Mentions:    Fields:    
    21. Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large-Scale Data to Inform Therapeutic Directions. Oncologist. 2021 Jan; 26(1):e78-e89. Jardim DL, Millis SZ, Ross JS, Woo MS, Ali SM, Kurzrock R. PMID: 32885893.
      View in: PubMed   Mentions:    Fields:    
    22. Unique Genomic Landscape of High-Grade Neuroendocrine Cervical Carcinoma: Implications for Rethinking Current Treatment Paradigms. JCO Precis Oncol. 2020; 4. Eskander RN, Elvin J, Gay L, Ross JS, Miller VA, Kurzrock R. PMID: 33015532.
      View in: PubMed   Mentions:
    23. Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers. Int J Cancer. 2021 Feb 01; 148(3):702-712. Okamura R, Kurzrock R, Mallory RJ, Fanta PT, Burgoyne AM, Clary BM, Kato S, Sicklick JK. PMID: 32700810.
      View in: PubMed   Mentions: 2     Fields:    
    24. Selpercatinib Aimed at RET-Altered Cancers. N Engl J Med. 2020 08 27; 383(9):868-869. Kurzrock R. PMID: 32846067.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    25. Circulating Tumor Cells: From the Laboratory to the Cancer Clinic. Cancers (Basel). 2020 Aug 21; 12(9). Agashe R, Kurzrock R. PMID: 32825548.
      View in: PubMed   Mentions:
    26. Letter responds to comment on "intention-to-treat analysis in precision oncology: A cautious interpretation". Eur J Cancer. 2020 10; 138:228. Sicklick J, Kato S, Kurzrock R. PMID: 32839070.
      View in: PubMed   Mentions:    Fields:    
    27. BAP1: Not just a BRCA1-associated protein. Cancer Treat Rev. 2020 Nov; 90:102091. Louie BH, Kurzrock R. PMID: 32877777.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    28. Machine learning model to predict oncologic outcomes for drugs in randomized clinical trials. Int J Cancer. 2020 Nov 01; 147(9):2537-2549. PMID: 32745254.
      View in: PubMed   Mentions:    Fields:    
    29. Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases. Ann Surg Oncol. 2020 Sep; 27(9):3259-3267. PMID: 32767050.
      View in: PubMed   Mentions:    Fields:    
    30. The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) =10: a decision centered on empowering patients and their physicians. Ann Oncol. 2020 09; 31(9):1115-1118. Subbiah V, Solit DB, Chan TA, Kurzrock R. PMID: 32771306.
      View in: PubMed   Mentions: 2     Fields:    
    31. Therapeutic Implications of Epidermal Growth Factor Receptor (EGFR) in the Treatment of Metastatic Gastric/GEJ Cancer. Front Oncol. 2020; 10:1312. Adashek JJ, Arroyo-Martinez Y, Menta AK, Kurzrock R, Kato S. PMID: 32850413.
      View in: PubMed   Mentions:
    32. High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers. Mol Cancer Ther. 2020 10; 19(10):2139-2145. Riviere P, Goodman AM, Okamura R, Barkauskas DA, Whitchurch TJ, Lee S, Khalid N, Collier R, Mareboina M, Frampton GM, Fabrizio D, Sharabi AB, Kato S, Kurzrock R. PMID: 32747422.
      View in: PubMed   Mentions: 1     Fields:    
    33. Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing. Genome Med. 2020 07 09; 12(1):61. Boichard A, Wagner MJ, Kurzrock R. PMID: 32646514.
      View in: PubMed   Mentions:    Fields:    
    34. Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy. Mol Oncol. 2020 08; 14(8):1680-1694. Pham TV, Boichard A, Goodman A, Riviere P, Yeerna H, Tamayo P, Kurzrock R. PMID: 32530570.
      View in: PubMed   Mentions: 1     Fields:    
    35. IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers. Cancers (Basel). 2020 Jul 02; 12(7). Amin HM, Morani AC, Daw NC, Lamhamedi-Cherradi SE, Subbiah V, Menegaz BA, Vishwamitra D, Eskandari G, George B, Benjamin RS, Patel S, Song J, Lazar AJ, Wang WL, Kurzrock R, Pappo A, Anderson PM, Schwartz GK, Araujo D, Cuglievan B, Ratan R, McCall D, Mohiuddin S, Livingston JA, Molina ER, Naing A, Ludwig JA. PMID: 32630797.
      View in: PubMed   Mentions:
    36. Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy. Cureus. 2020 Jul 02; 12(7):e8967. Cohen PR, Nikanjam M, Kato S, Goodman AM, Kurzrock R. PMID: 32766009.
      View in: PubMed   Mentions:
    37. Reply to "Effective therapy for advanced basal cell carcinoma". J Am Acad Dermatol. 2020 Jun 29. Cohen PR, Kurzrock R. PMID: 32615156.
      View in: PubMed   Mentions:    Fields:    
    38. Tumor mutational burden is not predictive of cytotoxic chemotherapy response. Oncoimmunology. 2020 06 24; 9(1):1781997. Nikanjam M, Riviere P, Goodman A, Barkauskas DA, Frampton G, Kurzrock R. PMID: 32923144.
      View in: PubMed   Mentions:
    39. Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients. Oncoimmunology. 2020 06 10; 9(1):1773200. Zhang T, Pabla S, Lenzo FL, Conroy JM, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Giamo V, Andreas J, Wang Y, Bshara W, Madden KG, Shirai K, Dragnev K, Tafe LJ, Gupta R, Zhu J, Labriola M, McCall S, George DJ, Ghatalia P, Dayyani F, Edwards R, Park MS, Singh R, Jacob R, George S, Xu B, Zibelman M, Kurzrock R, Morrison C. PMID: 32923131.
      View in: PubMed   Mentions:
    40. Transcriptomic silencing as a potential mechanism of treatment resistance. JCI Insight. 2020 06 04; 5(11). Adashek JJ, Kato S, Parulkar R, Szeto CW, Sanborn JZ, Vaske CJ, Benz SC, Reddy SK, Kurzrock R. PMID: 32493840.
      View in: PubMed   Mentions:    Fields:    
    41. New therapeutic approaches to overcoming resistant EGFR exon 20 alterations. Crit Rev Oncol Hematol. 2020 Jul; 151:102990. Li AM, Boichard A, Felip E, Kurzrock R. PMID: 32485428.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    42. MHC-I genotype and tumor mutational burden predict response to immunotherapy. Genome Med. 2020 05 19; 12(1):45. Goodman AM, Castro A, Pyke RM, Okamura R, Kato S, Riviere P, Frampton G, Sokol E, Zhang X, Ball ED, Carter H, Kurzrock R. PMID: 32430031.
      View in: PubMed   Mentions: 4     Fields:    
    43. Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response. Clin Cancer Res. 2020 05 15; 26(10):2434. Patel SP, Othus M, Chae YK, Kurzrock R. PMID: 32414761.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    44. Precision oncology: the intention-to-treat analysis fallacy. Eur J Cancer. 2020 07; 133:25-28. Sicklick JK, Kato S, Okamura R, Kurzrock R. PMID: 32422506.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    45. Dual Checkpoint Blockade in a Neuroendocrine Carcinoma With Dual PD-L1/PD-L2 Amplification and High Tumor Mutational Burden. JCO Precis Oncol. 2020; 4. Gong J, Patel S, Adashek JJ, Frishberg D, Guan M, Placencio-Hickok VR, Gangi A, Gresham G, Tuli R, Chae YK, Kurzrock R, Hendifar AE. PMID: 33215052.
      View in: PubMed   Mentions:
    46. Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. Exp Hematol Oncol. 2020; 9:7. Subbiah V, Dumbrava EI, Jiang Y, Thein KZ, Naing A, Hong DS, Fu S, Piha-Paul SA, Tsimberidou AM, Janku F, Meric-Bernstam F, Kurzrock R, Falchook G. PMID: 32337094.
      View in: PubMed   Mentions:
    47. ASO Author Reflections: Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases. Ann Surg Oncol. 2020 Sep; 27(9):3268-3269. Baumgartner JM, Riviere P, Kurzrock R. PMID: 32303875.
      View in: PubMed   Mentions:    Fields:    
    48. Concordance between TP53 alterations in blood and tissue: impact of time interval, biopsy site, cancer type and circulating tumor DNA burden. Mol Oncol. 2020 06; 14(6):1242-1251. Bieg-Bourne CC, Okamura R, Kurzrock R. PMID: 32187847.
      View in: PubMed   Mentions:    Fields:    
    49. Snapshot: Trial Types in Precision Medicine. Cell. 2020 04 02; 181(1):208-208.e1. Dickson D, Johnson J, Bergan R, Owens R, Subbiah V, Kurzrock R. PMID: 32243791.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    50. Review of precision cancer medicine: Evolution of the treatment paradigm. Cancer Treat Rev. 2020 Jun; 86:102019. Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R. PMID: 32251926.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    51. Total Number of Alterations in Liquid Biopsies Is an Independent Predictor of Survival in Patients With Advanced Cancers. JCO Precis Oncol. 2020; 4. Vu P, Khagi Y, Riviere P, Goodman A, Kurzrock R. PMID: 32923910.
      View in: PubMed   Mentions:
    52. Basal cell carcinoma: Management of advanced or metastatic cancer with checkpoint inhibitors and concurrent paradoxical development of new superficial tumors. J Am Acad Dermatol. 2020 06; 82(6):e253-e254. Cohen PR, Kurzrock R. PMID: 32109540.
      View in: PubMed   Mentions: 1     Fields:    
    53. Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. Oncoimmunology. 2020; 9(1):1708065. Kato S, Okamura R, Kumaki Y, Ikeda S, Nikanjam M, Eskander R, Goodman A, Lee S, Glenn ST, Dressman D, Papanicolau-Sengos A, Lenzo FL, Morrison C, Kurzrock R. PMID: 32117584.
      View in: PubMed   Mentions:
    54. The paradox of cancer genes in non-malignant conditions: implications for precision medicine. Genome Med. 2020 02 17; 12(1):16. Adashek JJ, Kato S, Lippman SM, Kurzrock R. PMID: 32066498.
      View in: PubMed   Mentions: 1     Fields:    
    55. Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors. Cancer Chemother Pharmacol. 2020 04; 85(4):673-683. Tolcher AW, Kurzrock R, Valero V, Gonzalez R, Heist RS, Tan AR, Means-Powell J, Werner TL, Becerra C, Wang C, Leonowens C, Kalyana-Sundaram S, Kleha JF, Gauvin J, D'Amelio AM, Ellis C, Ibrahim N, Yan L. PMID: 32062691.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    56. New drug approvals in oncology. Nat Rev Clin Oncol. 2020 03; 17(3):140-146. Kurzrock R, Kantarjian HM, Kesselheim AS, Sigal EV. PMID: 32020042.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    57. Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials. Lancet Haematol. 2020 Mar; 7(3):e209-e217. van Rhee F, Casper C, Voorhees PM, Fayad LE, Gibson D, Kanhai K, Kurzrock R. PMID: 32027862.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    58. ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy. J Immunother Cancer. 2020 Feb; 8(1). Okamura R, Kato S, Lee S, Jimenez RE, Sicklick JK, Kurzrock R. PMID: 32111729.
      View in: PubMed   Mentions: 6     Fields:    
    59. Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies. Int J Cancer. 2020 Jun 15; 146(12):3450-3460. Kato S, Okamura R, Sicklick JK, Daniels GA, Hong DS, Goodman A, Weihe E, Lee S, Khalid N, Collier R, Mareboina M, Riviere P, Whitchurch TJ, Fanta PT, Lippman SM, Kurzrock R. PMID: 31782524.
      View in: PubMed   Mentions: 1     Fields:    
    60. A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors. Clin Cancer Res. 2020 05 15; 26(10):2290-2296. Patel SP, Othus M, Chae YK, Giles FJ, Hansel DE, Singh PP, Fontaine A, Shah MH, Kasi A, Baghdadi TA, Matrana M, Gatalica Z, Korn WM, Hayward J, McLeod C, Chen HX, Sharon E, Mayerson E, Ryan CW, Plets M, Blanke CD, Kurzrock R. PMID: 31969335.
      View in: PubMed   Mentions: 13     Fields:    
    61. Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds. Oncoimmunology. 2020; 9(1):1710052. Jardim DL, De Melo Gagliato D, Nikanjam M, Barkauskas DA, Kurzrock R. PMID: 32002305.
      View in: PubMed   Mentions:
    62. The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments. Cancers (Basel). 2020 Jan 09; 12(1). Boichard A, Richard SB, Kurzrock R. PMID: 31936627.
      View in: PubMed   Mentions:
    63. The Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine. Cell. 2020 01 09; 180(1):9-14. Dickson D, Johnson J, Bergan R, Owens R, Subbiah V, Kurzrock R. PMID: 31951522.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    64. Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. J Hematol Oncol. 2019 12 30; 12(1):145. Tsimberidou AM, Hong DS, Wheler JJ, Falchook GS, Janku F, Naing A, Fu S, Piha-Paul S, Cartwright C, Broaddus RR, Nogueras Gonzalez GM, Hwu P, Kurzrock R. PMID: 31888672.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    65. First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors. Clin Cancer Res. 2020 03 15; 26(6):1237-1246. Falchook GS, Kurzrock R, Amin HM, Xiong W, Fu S, Piha-Paul SA, Janku F, Eskandari G, Catenacci DV, Klevesath M, Bruns R, Stammberger U, Johne A, Bladt F, Friese-Hamim M, Girard P, El Bawab S, Hong DS. PMID: 31822497.
      View in: PubMed   Mentions: 4     Fields:    
    66. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. Ann Oncol. 2020 03; 31(3):412-421. Kurzrock R, Bowles DW, Kang H, Meric-Bernstam F, Hainsworth J, Spigel DR, Bose R, Burris H, Sweeney CJ, Beattie MS, Blotner S, Schulze K, Cuchelkar V, Swanton C. PMID: 32067683.
      View in: PubMed   Mentions: 4     Fields:    
    67. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. J Hematol Oncol. 2019 12 04; 12(1):130. Patel H, Okamura R, Fanta P, Patel C, Lanman RB, Raymond VM, Kato S, Kurzrock R. PMID: 31801585.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    68. Targeting fusions for improved outcomes in oncology treatment. Cancer. 2020 03 15; 126(6):1315-1321. Nikanjam M, Okamura R, Barkauskas DA, Kurzrock R. PMID: 31794076.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    69. Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress? Oncologist. 2019 Nov 20. Adashek JJ, Kato S, Ferrara R, Lo Russo G, Kurzrock R. PMID: 31748338.
      View in: PubMed   Mentions:    Fields:    
    70. Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress? Oncologist. 2020 02; 25(2):94-98. Adashek JJ, Kato S, Ferrara R, Lo Russo G, Kurzrock R. PMID: 32043794.
      View in: PubMed   Mentions: 2     Fields:    
    71. Real-World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim-Chester Disease. Oncologist. 2020 02; 25(2):e386-e390. Saunders IM, Goodman AM, Kurzrock R. PMID: 32043767.
      View in: PubMed   Mentions:    Fields:    
    72. Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals. Ann Oncol. 2019 10 01; 30(10):1647-1652. Kurzrock R, Gurski LA, Carlson RW, Ettinger DS, Horwitz SM, Kumar SK, Million L, von Mehren M, Benson AB. PMID: 31373348.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    73. Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics. Ann Oncol. 2019 10 01; 30(10):1675. Nikanjam M, Cohen PR, Kato S, Sicklick JK, Kurzrock R. PMID: 31408092.
      View in: PubMed   Mentions: 1     Fields:    
    74. Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients. Int J Cancer. 2020 06 01; 146(11):3087-3097. Nikanjam M, Arguello D, Gatalica Z, Swensen J, Barkauskas DA, Kurzrock R. PMID: 31479512.
      View in: PubMed   Mentions: 5     Fields:    
    75. Mutated TP53 is a marker of increased VEGF expression: analysis of 7,525 pan-cancer tissues. Cancer Biol Ther. 2020; 21(1):95-100. Li AM, Boichard A, Kurzrock R. PMID: 31564192.
      View in: PubMed   Mentions: 4     Fields:    
    76. Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. Clin Cancer Res. 2020 03 15; 26(6):1247-1257. Falchook G, Rosen S, LoRusso P, Watts J, Gupta S, Coombs CC, Talpaz M, Kurzrock R, Mita M, Cassaday R, Harb W, Peguero J, Smith DC, Piha-Paul SA, Szmulewitz R, Noel MS, Yeleswaram S, Liu P, Switzky J, Zhou G, Zheng F, Mehta A. PMID: 31527168.
      View in: PubMed   Mentions: 2     Fields:    
    77. Phase I trials as valid therapeutic options for patients with cancer. Nat Rev Clin Oncol. 2019 12; 16(12):773-778. Adashek JJ, LoRusso PM, Hong DS, Kurzrock R. PMID: 31477881.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    78. Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy. Cancer Immunol Res. 2019 10; 7(10):1570-1573. Goodman AM, Sokol ES, Frampton GM, Lippman SM, Kurzrock R. PMID: 31405947.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    79. Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. Clin Cancer Res. 2019 10 15; 25(20):6107-6118. Kaseb AO, Sánchez NS, Sen S, Kelley RK, Tan B, Bocobo AG, Lim KH, Abdel-Wahab R, Uemura M, Pestana RC, Qiao W, Xiao L, Morris J, Amin HM, Hassan MM, Rashid A, Banks KC, Lanman RB, Talasaz A, Mills-Shaw KR, George B, Haque A, Raghav KPS, Wolff RA, Yao JC, Meric-Bernstam F, Ikeda S, Kurzrock R. PMID: 31363003.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    80. Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics. . 2019 10; 18(10):1852-1862. Choi IS, Kato S, Fanta PT, Leichman L, Okamura R, Raymond VM, Lanman RB, Lippman SM, Kurzrock R. PMID: 31320401.
      View in: PubMed   Mentions:
    81. Temporal and spatial effects and survival outcomes associated with concordance between tissue and blood KRAS alterations in the pan-cancer setting. Int J Cancer. 2020 01 15; 146(2):566-576. Mardinian K, Okamura R, Kato S, Kurzrock R. PMID: 31199507.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    82. Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. Oncotarget. 2019 Jun 18; 10(40):4018-4025. Ang C, Klempner SJ, Ali SM, Madison R, Ross JS, Severson EA, Fabrizio D, Goodman A, Kurzrock R, Suh J, Millis SZ. PMID: 31258846.
      View in: PubMed   Mentions: 11     Fields:    
    83. A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. Clin Cancer Res. 2019 09 15; 25(18):5475-5484. Kurzrock R, Ball DW, Zahurak ML, Nelkin BD, Subbiah V, Ahmed S, O'Connor A, Karunsena E, Parkinson RM, Bishop JA, Ha Y, Sharma R, Gocke CD, Zinner R, Rudek MA, Sherman SI, Azad NS. PMID: 31186313.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    84. Remembering the forgotten child: the role of immune checkpoint inhibition in patients with human immunod eficiency virus and cancer. J Immunother Cancer. 2019 05 22; 7(1):130. Adashek JJ, Junior PNA, Galanina N, Kurzrock R. PMID: 31113482.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    85. Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis. . 2019 06; 18(6):1149-1157. Janku F, Diamond EL, Goodman AM, Raghavan VK, Barnes TG, Kato S, Abdel-Wahab O, Durham BH, Meric-Bernstam F, Kurzrock R. PMID: 31015311.
      View in: PubMed   Mentions:
    86. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med. 2019 05; 25(5):751-758. Rodon J, Soria JC, Berger R, Miller WH, Rubin E, Kugel A, Tsimberidou A, Saintigny P, Ackerstein A, Braña I, Loriot Y, Afshar M, Miller V, Wunder F, Bresson C, Martini JF, Raynaud J, Mendelsohn J, Batist G, Onn A, Tabernero J, Schilsky RL, Lazar V, Lee JJ, Kurzrock R. PMID: 31011205.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    87. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med. 2019 05; 25(5):744-750. Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, De P, Krie A, Piccioni DE, Miller VA, Ross JS, Benson A, Webster J, Stephens PJ, Lee JJ, Fanta PT, Lippman SM, Leyland-Jones B, Kurzrock R. PMID: 31011206.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCTClinical Trials
    88. Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness. Cancer Immunol Res. 2019 06; 7(6):866-873. Goodman AM, Kato S, Chattopadhyay R, Okamura R, Saunders IM, Montesion M, Frampton GM, Miller VA, Daniels GA, Kurzrock R. PMID: 31003990.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    89. Schnitzler syndrome associated with MYD88 L265P mutation. JAAD Case Rep. 2019 Apr; 5(4):312-316. Goodman AM, Cohen PR, Li A, Hinds B, Kurzrock R. PMID: 30989098.
      View in: PubMed   Mentions:
    90. Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies. . 2019 05; 18(5):1001-1011. Shatsky R, Parker BA, Bui NQ, Helsten T, Schwab RB, Boles SG, Kurzrock R. PMID: 30926636.
      View in: PubMed   Mentions:
    91. Immune Escape of AML Cells after Transplantation. N Engl J Med. 2019 03 28; 380(13):1289. Goodman AM, Kurzrock R. PMID: 30917272.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    92. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019 04; 20(4):518-530. Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, Swanton C, Kurzrock R, Burris H, Sweeney C, Bose R, Spigel DR, Beattie MS, Blotner S, Stone A, Schulze K, Cuchelkar V, Hainsworth J. PMID: 30857956.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
    93. Novel patterns of response under immunotherapy. Ann Oncol. 2019 03 01; 30(3):385-396. Borcoman E, Kanjanapan Y, Champiat S, Kato S, Servois V, Kurzrock R, Goel S, Bedard P, Le Tourneau C. PMID: 30657859.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    94. Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients. J Immunother Cancer. 2019 02 01; 7(1):27. Pabla S, Conroy JM, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Hagen J, Giamo V, Andreas J, Lenzo FL, Yirong W, Dy GK, Yau E, Early A, Chen H, Bshara W, Madden KG, Shirai K, Dragnev K, Tafe LJ, Marin D, Zhu J, Clarke J, Labriola M, McCall S, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Dressler L, Steciuk M, Binns O, Kasuganti D, Shah N, Ernstoff M, Odunsi K, Kurzrock R, Gardner M, Galluzzi L, Morrison C. PMID: 30709424.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    95. Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival. JCO Precis Oncol. 2019; 3. Kato S, Schwaederlé MC, Fanta PT, Okamura R, Leichman L, Lippman SM, Lanman RB, Raymond VM, Talasaz A, Kurzrock R. PMID: 31032472.
      View in: PubMed   Mentions:
    96. Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies. JCO Precis Oncol. 2019; 3. Kato S, Okamura R, Mareboina M, Lee S, Goodman A, Patel SP, Fanta PT, Schwab RB, Vu P, Raymond VM, Lanman RB, Sicklick JK, Lippman SM, Kurzrock R. PMID: 31058253.
      View in: PubMed   Mentions:
    97. Identification of targets for prostate cancer immunotherapy. Prostate. 2019 04; 79(5):498-505. Papanicolau-Sengos A, Yang Y, Pabla S, Lenzo FL, Kato S, Kurzrock R, DePietro P, Nesline M, Conroy J, Glenn S, Chatta G, Morrison C. PMID: 30614027.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    98. Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol. 2019 01 01; 5(1):e183773. Falchook G, Coleman RL, Roszak A, Behbakht K, Matulonis U, Ray-Coquard I, Sawrycki P, Duska LR, Tew W, Ghamande S, Lesoin A, Schwartz PE, Buscema J, Fabbro M, Lortholary A, Goff B, Kurzrock R, Martin LP, Gray HJ, Fu S, Sheldon-Waniga E, Lin HM, Venkatakrishnan K, Zhou X, Leonard EJ, Schilder RJ. PMID: 30347019.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    99. Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities. Cancer. 2019 04 01; 125(7):1185-1199. Millis SZ, Jardim DL, Albacker L, Ross JS, Miller VA, Ali SM, Kurzrock R. PMID: 30582752.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    100. APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy. Oncoimmunology. 2019; 8(3):1550341. Boichard A, Pham TV, Yeerna H, Goodman A, Tamayo P, Lippman S, Frampton GM, Tsigelny IF, Kurzrock R. PMID: 30723579.
      View in: PubMed   Mentions:
    101. Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials. Cancers (Basel). 2018 Dec 21; 11(1). Galanina N, Bejar R, Choi M, Goodman A, Wieduwilt M, Mulroney C, Kim L, Yeerna H, Tamayo P, Vergilio JA, Mughal TI, Miller V, Jamieson C, Kurzrock R. PMID: 30583461.
      View in: PubMed   Mentions:
    102. Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes. Breast. 2019 Apr; 44:29-32. Tray N, Taff J, Singh B, Suh J, Ngo N, Kwa M, Troxel AB, Chae YK, Kurzrock R, Patel SP, Sharon E, Denkert C, Ross JS, Adams S. PMID: 30609392.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    103. Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1a antibody, in a phase III randomized study of advanced colorectal cancer. Oncoimmunology. 2019; 8(3):1551651. Kurzrock R, Hickish T, Wyrwicz L, Saunders M, Wu Q, Stecher M, Mohanty P, Dinarello CA, Simard J. PMID: 30723583.
      View in: PubMed   Mentions:
    104. Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer Patients. . 2019 02; 18(2):448-458. Jensen TJ, Goodman AM, Kato S, Ellison CK, Daniels GA, Kim L, Nakashe P, McCarthy E, Mazloom AR, McLennan G, Grosu DS, Ehrich M, Kurzrock R. PMID: 30523049.
      View in: PubMed   Mentions:
    105. Dosing Oncology Therapeutics in Combination Therapy for Renal Dysfunction: The University of California San Diego Study of Personalized Cancer Therapy to Determine Response and Toxicity (UCSD-PREDICT) Experience. Cureus. 2018 Nov 26; 10(11):e3634. Nikanjam M, Wing J, Capparelli E, Kurzrock R. PMID: 30705793.
      View in: PubMed   Mentions:
    106. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. J Immunother Cancer. 2018 11 16; 6(1):119. Reilley MJ, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Curran M, Liu Q, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MVP, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR, Hong DS. PMID: 30446007.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    107. Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics. JCO Precis Oncol. 2018; 2018. Okamura R, Boichard A, Kato S, Sicklick JK, Bazhenova L, Kurzrock R. PMID: 30637364.
      View in: PubMed   Mentions:
    108. ASO Author Reflections: Circulating Tumor DNA in Peritoneal Carcinomatosis. Ann Surg Oncol. 2018 12; 25(Suppl 3):772-773. Baumgartner JM, Kurzrock R. PMID: 30421042.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    109. An avatar for precision cancer therapy. Nat Biotechnol. 2018 11 09; 36(11):1053-1055. Kato S, Kurzrock R. PMID: 30412185.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    110. Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics. Ann Oncol. 2018 11 01; 29(11):2192-2199. Nikanjam M, Cohen PR, Kato S, Sicklick JK, Kurzrock R. PMID: 30219896.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    111. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. Cancer. 2019 02 01; 125(3):463-472. Bhatty M, Kato S, Piha-Paul SA, Naing A, Subbiah V, Huang HJ, Karp DD, Tsimberidou AM, Zinner RG, Hwu WJ, Javle M, Patel SP, Hu MI, Varadhachary GR, Conley AP, Ramzanali NM, Holley VR, Kurzrock R, Meric-Bernstam F, Kwang Chae Y, Kim KB, Falchook GS, Janku F. PMID: 30383888.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    112. The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match. Oncologist. 2019 01; 24(1):1-3. Subbiah V, Kurzrock R. PMID: 30352943.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    113. Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma. Clin Cancer Res. 2018 12 15; 24(24):6248-6256. Kato S, Okamura R, Baumgartner JM, Patel H, Leichman L, Kelly K, Sicklick JK, Fanta PT, Lippman SM, Kurzrock R. PMID: 30348637.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    114. Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. J Clin Oncol. 2018 Oct 19; JCO1800328. Slavin TP, Banks KC, Chudova D, Oxnard GR, Odegaard JI, Nagy RJ, Tsang KWK, Neuhausen SL, Gray SW, Cristofanilli M, Rodriguez AA, Bardia A, Leyland-Jones B, Janicek MF, Lilly M, Sonpavde G, Lee CE, Lanman RB, Meric-Bernstam F, Kurzrock R, Weitzel JN. PMID: 30339520.
      View in: PubMed   Mentions: 11     Fields:    
    115. Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing. . 2019; 20(2):219-226. Ikeda S, Elkin SK, Tomson BN, Carter JL, Kurzrock R. PMID: 30339521.
      View in: PubMed   Mentions:
    116. Radiation Therapy Combined With Checkpoint Blockade Immunotherapy for Metastatic Undifferentiated Pleomorphic Sarcoma of the Maxillary Sinus With a Complete Response. Front Oncol. 2018; 8:435. Guram K, Nunez M, Einck J, Mell LK, Cohen E, Sanders PD, Miyauchi S, Weihe E, Kurzrock R, Boles S, Sharabi AB. PMID: 30386736.
      View in: PubMed   Mentions:
    117. Successful implementation of genomically based treatment of chemotherapy refractory peripheral T-cell lymphoma (PTCL). . 2019; 20(3):247-251. Galanina N, Kurzrock R. PMID: 30307363.
      View in: PubMed   Mentions:
    118. Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology. Integr Cancer Ther. 2018 12; 17(4):1012-1015. Jardim DL, de Melo Gagliato D, Kurzrock R. PMID: 30229677.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    119. GNAS, GNAQ, and GNA11 alterations in patients with diverse cancers. Cancer. 2018 10 15; 124(20):4080-4089. Parish AJ, Nguyen V, Goodman AM, Murugesan K, Frampton GM, Kurzrock R. PMID: 30204251.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    120. Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade. Cancer Immunol Res. 2018 10; 6(10):1129-1135. Galanina N, Goodman AM, Cohen PR, Frampton GM, Kurzrock R. PMID: 30194084.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    121. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018 11 15; 132(20):2115-2124. van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC. PMID: 30181172.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    122. Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors. JAMA Oncol. 2018 09 01; 4(9):1237-1244. Goodman AM, Piccioni D, Kato S, Boichard A, Wang HY, Frampton G, Lippman SM, Connelly C, Fabrizio D, Miller V, Sicklick JK, Kurzrock R. PMID: 29902298.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    123. Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. Oncologist. 2018 11; 23(11):1300-1309. Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Hong D, Kurzrock R, Hortobagyi GN, Janku F, Moulder SL. PMID: 30139837.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    124. JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis. . 2018 08 03; 19(8):664-668. Choi MY, Kato S, Wang HY, Lin JH, Lanman RB, Kurzrock R. PMID: 29565699.
      View in: PubMed   Mentions:
    125. Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies. JCO Precis Oncol. 2018; 2018. Kato S, Ross JS, Gay L, Dayyani F, Roszik J, Subbiah V, Kurzrock R. PMID: 30148248.
      View in: PubMed   Mentions:
    126. Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors. Oncotarget. 2018 Jun 22; 9(48):28842-28848. Subbiah IM, Tang C, Rao A, Falchook GS, Subbiah V, Tsimberidou AM, Karp D, Kurzrock R, Hong DS. PMID: 29989021.
      View in: PubMed   Mentions: 2     Fields:    
    127. Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival. Ann Surg Oncol. 2018 Aug; 25(8):2400-2408. Baumgartner JM, Raymond VM, Lanman RB, Tran L, Kelly KJ, Lowy AM, Kurzrock R. PMID: 29948422.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    128. MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis. J Hematol Oncol. 2018 06 04; 11(1):76. Ikeda S, Schwaederle M, Mohindra M, Fontes Jardim DL, Kurzrock R. PMID: 29866143.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    129. Reply to J.J. Tao et al. J Clin Oncol. 2018 08 10; 36(23):2451. Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. PMID: 29856693.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    130. Cancer research in the United States: A critical review of current status and proposal for alternative models. Cancer. 2018 07 15; 124(14):2881-2889. Kantarjian HM, Prat F, Steensma DP, Kurzrock R, Stewart DJ, Sekeres MA, Leveque J. PMID: 29757456.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    131. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. Br J Cancer. 2018 05; 118(11):1419-1424. Sen S, Kato S, Agarwal R, Piha-Paul S, Hess K, Karp D, Janku F, Fu S, Naing A, Pant S, Falchook G, Tang C, Wu X, Ye Y, Tsimberidou A, Subbiah V, Kurzrock R, Byers L, Westin S, Lim J, Bean S, Bass A, Nguyen L, Meric-Bernstam F, Hong D. PMID: 29695765.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    132. Razelle Kurzrock and Shumei Kato on Immunotherapy and Hyperprogression of Disease. Oncology (Williston Park). 2018 04 15; 32(4):150-1, 163. Kurzrock R, Kato S. PMID: 29684227.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    133. The importance of greater speed in drug development for advanced malignancies. Cancer Med. 2018 05; 7(5):1824-1836. Stewart DJ, Stewart AA, Wheatley-Price P, Batist G, Kantarjian HM, Schiller J, Clemons M, Bradford JP, Gillespie L, Kurzrock R. PMID: 29601671.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    134. Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial. Br J Cancer. 2018 04; 118(8):1042-1050. Maitland ML, Piha-Paul S, Falchook G, Kurzrock R, Nguyen L, Janisch L, Karovic S, McKee M, Hoening E, Wong S, Munasinghe W, Palma J, Donawho C, Lian GK, Ansell P, Ratain MJ, Hong D. PMID: 29551775.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    135. Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma. Oncologist. 2018 05; 23(5):586-593. Ikeda S, Tsigelny IF, Skjevik ÅA, Kono Y, Mendler M, Kuo A, Sicklick JK, Heestand G, Banks KC, Talasaz A, Lanman RB, Lippman S, Kurzrock R. PMID: 29487225.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    136. Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics. . 2018 05; 17(5):1114-1122. Ikeda S, Lim JS, Kurzrock R. PMID: 29483209.
      View in: PubMed   Mentions:
    137. TP53 mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [18F] fluorodeoxyglucose (18F-FDG PET). Oncotarget. 2018 Mar 06; 9(18):14306-14310. Chang GH, Kurzrock R, Tran L, Schwaederle M, Hoh CK. PMID: 29581845.
      View in: PubMed   Mentions: 2     Fields:    
    138. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus. Clin Cancer Res. 2018 04 15; 24(8):1881-1890. Schrock AB, Pavlick D, Klempner SJ, Chung JH, Forcier B, Welsh A, Young L, Leyland-Jones B, Bordoni R, Carvajal RD, Chao J, Kurzrock R, Sicklick JK, Ross JS, Stephens PJ, Devoe C, Braiteh F, Ali SM, Miller VA. PMID: 29363525.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    139. Challenging Standard-of-Care Paradigms in the Precision Oncology Era. Trends Cancer. 2018 02; 4(2):101-109. Subbiah V, Kurzrock R. PMID: 29458960.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    140. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. J Clin Oncol. 2018 02 20; 36(6):536-542. Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. PMID: 29320312.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansCTClinical Trials
    141. Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies. Oncoimmunology. 2018; 7(3):e1404217. Goodman AM, Kato S, Cohen PR, Boichard A, Frampton G, Miller V, Stephens PJ, Daniels GA, Kurzrock R. PMID: 29399405.
      View in: PubMed   Mentions:
    142. Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients. Cancer. 2018 03 15; 124(6):1288-1296. Schwaederle M, Krishnamurthy N, Daniels GA, Piccioni DE, Kesari S, Fanta PT, Schwab RB, Patel SP, Parker BA, Kurzrock R. PMID: 29211306.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    143. Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors. Clin Cancer Res. 2018 04 15; 24(8):1785-1794. Jardim DL, de Melo Gagliato D, Giles FJ, Kurzrock R. PMID: 29212781.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimals
    144. Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining "Actionability" of a Molecular Lesion and Patient Management Support. . 2017 Dec; 16(12):2645-2655. Chae YK, Pan AP, Davis AA, Patel SP, Carneiro BA, Kurzrock R, Giles FJ. PMID: 29203694.
      View in: PubMed   Mentions:
    145. Core Clinical Data Elements for Cancer Genomic Repositories: A Multi-stakeholder Consensus. Cell. 2017 Nov 16; 171(5):982-986. Conley RB, Dickson D, Zenklusen JC, Al Naber J, Messner DA, Atasoy A, Chaihorsky L, Collyar D, Compton C, Ferguson M, Khozin S, Klein RD, Kotte S, Kurzrock R, Lin CJ, Liu F, Marino I, McDonough R, McNeal A, Miller V, Schilsky RL, Wang LI. PMID: 29149611.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    146. Molecular Tumor Boards: Realizing Precision Oncology Therapy. Clin Pharmacol Ther. 2018 02; 103(2):206-209. Patel M, Kato SM, Kurzrock R. PMID: 29134641.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    147. The Mutational Landscape of Gastrointestinal Malignancies as Reflected by Circulating Tumor DNA. . 2018 01; 17(1):297-305. Riviere P, Fanta PT, Ikeda S, Baumgartner J, Heestand GM, Kurzrock R. PMID: 29133621.
      View in: PubMed   Mentions:
    148. Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors. Cancer Treat Rev. 2018 Jan; 62:50-60. Krishnamurthy N, Kurzrock R. PMID: 29169144.
      View in: PubMed   Mentions: 119     Fields:    Translation:HumansCells
    149. Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours. Eur J Cancer. 2017 11; 86:296-304. Schöffski P, Gordon M, Smith DC, Kurzrock R, Daud A, Vogelzang NJ, Lee Y, Scheffold C, Shapiro GI. PMID: 29059635.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    150. Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach. Oncologist. 2018 02; 23(2):171-178. Kato S, Kurasaki K, Ikeda S, Kurzrock R. PMID: 29038235.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    151. Genomics of Immunotherapy-Associated Hyperprogressors-Response. Clin Cancer Res. 2017 10 15; 23(20):6376. Kato S, Kurzrock R. PMID: 29030333.
      View in: PubMed   Mentions: 3     Fields:    
    152. Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy. Clin Cancer Res. 2017 Oct 01; 23(19):5729-5736. Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, Randall JM, Bazhenova LA, Kurzrock R. PMID: 28972084.
      View in: PubMed   Mentions: 52     Fields:    Translation:Humans
    153. Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability. Cancer Res. 2017 11 15; 77(22):6313-6320. Bieg-Bourne CC, Millis SZ, Piccioni DE, Fanta PT, Goldberg ME, Chmielecki J, Parker BA, Kurzrock R. PMID: 28939679.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    154. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. JCO Precis Oncol. 2017; 2017. Tsimberidou AM, Hong DS, Ye Y, Cartwright C, Wheler JJ, Falchook GS, Naing A, Fu S, Piha-Paul S, Janku F, Meric-Bernstam F, Hwu P, Kee B, Kies MS, Broaddus R, Mendelsohn J, Hess KR, Kurzrock R. PMID: 29082359.
      View in: PubMed   Mentions:
    155. The biology of Hepatocellular carcinoma: implications for genomic and immune therapies. Mol Cancer. 2017 08 30; 16(1):149. Khemlina G, Ikeda S, Kurzrock R. PMID: 28854942.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansAnimalsCells
    156. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. . 2017 11; 16(11):2598-2608. Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R. PMID: 28835386.
      View in: PubMed   Mentions:
    157. BRAF mutation as a novel driver of eosinophilic cystitis. . 2017 Sep 02; 18(9):655-659. Choi MY, Tsigelny IF, Boichard A, Skjevik ÅA, Shabaik A, Kurzrock R. PMID: 28829677.
      View in: PubMed   Mentions:
    158. Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing. Cancer Res. 2017 10 01; 77(19):5419-5427. Schwaederle M, Chattopadhyay R, Kato S, Fanta PT, Banks KC, Choi IS, Piccioni DE, Ikeda S, Talasaz A, Lanman RB, Bazhenova L, Kurzrock R. PMID: 28807936.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    159. Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease. Int J Mol Sci. 2017 Jul 31; 18(8). Cohen PR, Kato S, Goodman AM, Ikeda S, Kurzrock R. PMID: 28788102.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    160. A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma. Eur J Cancer. 2017 09; 83:229-236. Vergote IB, Smith DC, Berger R, Kurzrock R, Vogelzang NJ, Sella A, Wheler J, Lee Y, Foster PG, Weitzman R, Buckanovich RJ. PMID: 28755607.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    161. Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. Clin Cancer Res. 2017 Jul 20. Kehl KL, Fullmer CP, Fu S, George GC, Hess KR, Janku F, Karp DD, Kato S, Kizer CK, Kurzrock R, Naing A, Pant S, Piha-Paul SA, Subbiah V, Tsimberidou AM, Hong DS. PMID: 28729355.
      View in: PubMed   Mentions: 1     Fields:    
    162. Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients. Eur J Cancer. 2017 09; 83:80-87. Heestand GM, Schwaederle M, Gatalica Z, Arguello D, Kurzrock R. PMID: 28728050.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    163. Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit. J Natl Compr Canc Netw. 2017 07; 15(7):863-866. Kato S, Subbiah V, Kurzrock R. PMID: 28687573.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    164. Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities. Oncotarget. 2017 Sep 15; 8(40):67782-67789. Costa R, Costa RB, Talamantes SM, Helenoswki I, Carneiro BA, Chae YK, Gradishar WJ, Kurzrock R, Giles FJ. PMID: 28978071.
      View in: PubMed   Mentions: 5     Fields:    
    165. Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns. Oncoimmunology. 2017; 6(8):e1338997. Nikanjam M, Patel H, Kurzrock R. PMID: 28920006.
      View in: PubMed   Mentions:
    166. Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary. Cancer Res. 2017 08 15; 77(16):4238-4246. Kato S, Krishnamurthy N, Banks KC, De P, Williams K, Williams C, Leyland-Jones B, Lippman SM, Lanman RB, Kurzrock R. PMID: 28642281.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    167. Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center. Oncologist. 2017 06; 22(6):631-637. Sharabi A, Kim SS, Kato S, Sanders PD, Patel SP, Sanghvi P, Weihe E, Kurzrock R. PMID: 28550027.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    168. Debunking the Delusion That Precision Oncology Is an Illusion. Oncologist. 2017 08; 22(8):881-882. Subbiah V, Kurzrock R. PMID: 28550030.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    169. Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma. Clin Cancer Res. 2017 Sep 01; 23(17):5101-5111. Schwaederlé MC, Patel SP, Husain H, Ikeda M, Lanman RB, Banks KC, Talasaz A, Bazhenova L, Kurzrock R. PMID: 28539465.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    170. JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease. JAMA Dermatol. 2017 05 01; 153(5):449-452. Patel M, Ikeda S, Pilat SR, Kurzrock R. PMID: 28241173.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    171. Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology. . 2017 05; 16(5):948-955. Husain H, Nykin D, Bui N, Quan D, Gomez G, Woodward B, Venkatapathy S, Duttagupta R, Fung E, Lippman SM, Kurzrock R. PMID: 28468865.
      View in: PubMed   Mentions:
    172. Next Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients with Lymphoid Malignancies. JCO Precis Oncol. 2017 06; 1. Goodman AM, Choi M, Wieduwilt M, Mulroney C, Costello C, Frampton G, Miller V, Kurzrock R. PMID: 28681041.
      View in: PubMed   Mentions:
    173. Polycystic ovary syndrome in men. Med Hypotheses. 2017 06; 103:64. Cohen PR, Kurzrock R. PMID: 28571814.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    174. Dosing Three-Drug Combinations That Include Targeted Anti-Cancer Agents: Analysis of 37,763 Patients. Oncologist. 2017 05; 22(5):576-584. Nikanjam M, Liu S, Yang J, Kurzrock R. PMID: 28424323.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    175. Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine. Clin Cancer Res. 2017 Aug 15; 23(16):4716-4723. Husain H, Melnikova VO, Kosco K, Woodward B, More S, Pingle SC, Weihe E, Park BH, Tewari M, Erlander MG, Cohen E, Lippman SM, Kurzrock R. PMID: 28420725.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    176. Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma. Clin Cancer Res. 2017 08 01; 23(15):4027-4034. Subbiah V, Meyer C, Zinner R, Meric-Bernstam F, Zahurak ML, O'Connor A, Roszik J, Shaw K, Ludwig JA, Kurzrock R, Azad NA. PMID: 28377484.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    177. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol. 2017 Apr 01; 3(4):509-515. Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL. PMID: 27893038.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCellsCTClinical Trials
    178. Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. Clin Cancer Res. 2017 Aug 01; 23(15):4242-4250. Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. PMID: 28351930.
      View in: PubMed   Mentions: 182     Fields:    Translation:Humans
    179. Next generation predictive biomarkers for immune checkpoint inhibition. Cancer Metastasis Rev. 2017 03; 36(1):179-190. Khagi Y, Kurzrock R, Patel SP. PMID: 27873079.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansAnimals
    180. Systematic analysis of early phase clinical studies for patients with breast cancer: Inclusion of patients with brain metastasis. Cancer Treat Rev. 2017 Apr; 55:10-15. Costa R, Gill N, Rademaker AW, Carneiro BA, Chae YK, Kumthekar P, Gradishar WJ, Kurzrock R, Giles FJ. PMID: 28279895.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    181. Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors. Invest New Drugs. 2017 10; 35(5):616-626. Mita M, Fu S, Piha-Paul SA, Janku F, Mita A, Natale R, Guo W, Zhao C, Kurzrock R, Naing A. PMID: 28194539.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    182. Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer. . 2017 02; 16(2):265-272. Husain H, Scur M, Murtuza A, Bui N, Woodward B, Kurzrock R. PMID: 28159915.
      View in: PubMed   Mentions:
    183. High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations. Oncoimmunology. 2017; 6(3):e1284719. Boichard A, Tsigelny IF, Kurzrock R. PMID: 28405512.
      View in: PubMed   Mentions:
    184. Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. Br J Cancer. 2017 Feb 14; 116(4):432-440. Daud A, Kluger HM, Kurzrock R, Schimmoller F, Weitzman AL, Samuel TA, Moussa AH, Gordon MS, Shapiro GI. PMID: 28103611.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    185. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017 Mar 23; 129(12):1646-1657. Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, Simpson D, Liu AY, Menke D, Chandrakasan S, Lechowicz MJ, Wong RS, Pierson S, Paessler M, Rossi JF, Ide M, Ruth J, Croglio M, Suarez A, Krymskaya V, Chadburn A, Colleoni G, Nasta S, Jayanthan R, Nabel CS, Casper C, Dispenzieri A, Fosså A, Kelleher D, Kurzrock R, Voorhees P, Dogan A, Yoshizaki K, van Rhee F, Oksenhendler E, Jaffe ES, Elenitoba-Johnson KS, Lim MS. PMID: 28087540.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCells
    186. FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors. J Transl Med. 2016 12 14; 14(1):339. Shi E, Chmielecki J, Tang CM, Wang K, Heinrich MC, Kang G, Corless CL, Hong D, Fero KE, Murphy JD, Fanta PT, Ali SM, De Siena M, Burgoyne AM, Movva S, Madlensky L, Heestand GM, Trent JC, Kurzrock R, Morosini D, Ross JS, Harismendy O, Sicklick JK. PMID: 27974047.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    187. Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients. Clin Cancer Res. 2017 Mar 01; 23(5):1137-1148. Kurzrock R, Stewart DJ. PMID: 27940520.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    188. Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19?784 Diverse Solid Tumors. JAMA Oncol. 2016 Dec 01; 2(12):1565-1573. Millis SZ, Ikeda S, Reddy S, Gatalica Z, Kurzrock R. PMID: 27388585.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCells
    189. Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant Accrual. Clin Cancer Res. 2017 Mar 15; 23(6):1407-1413. Tang C, Hess KR, Sanders D, Davis SE, Buzdar AU, Kurzrock R, Lee JJ, Meric-Bernstam F, Hong DS. PMID: 27852698.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    190. Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review. Cancer Treat Rev. 2017 Jan; 52:12-21. Jardim DL, Groves ES, Breitfeld PP, Kurzrock R. PMID: 27883925.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    191. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol. 2017 04; 14(4):203-220. Goodman A, Patel SP, Kurzrock R. PMID: 27805626.
      View in: PubMed   Mentions: 96     Fields:    Translation:Humans
    192. Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis. JAMA Oncol. 2016 Nov 01; 2(11):1452-1459. Schwaederle M, Zhao M, Lee JJ, Lazar V, Leyland-Jones B, Schilsky RL, Mendelsohn J, Kurzrock R. PMID: 27273579.
      View in: PubMed   Mentions: 56     Fields:    Translation:Humans
    193. Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy. NPJ Genom Med. 2016; 1. Ikeda S, Goodman AM, Cohen PR, Jensen TJ, Ellison CK, Frampton G, Miller V, Patel SP, Kurzrock R. PMID: 27942391.
      View in: PubMed   Mentions:
    194. Outcomes of patients =65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER. Int J Cancer. 2017 Jan 01; 140(1):208-215. Subbiah IM, Wheler JJ, Hess KR, Hong DS, Naing A, Fu S, Kurzrock R, Tsimberidou AM. PMID: 27599876.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    195. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget. 2016 Oct 11; 7(41):67521-67531. Park H, Garrido-Laguna I, Naing A, Fu S, Falchook GS, Piha-Paul SA, Wheler JJ, Hong DS, Tsimberidou AM, Subbiah V, Zinner RG, Kaseb AO, Patel S, Fanale MA, Velez-Bravo VM, Meric-Bernstam F, Kurzrock R, Janku F. PMID: 27589687.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    196. Targeted therapies: What have we learned from SHIVA? Nat Rev Clin Oncol. 2016 12; 13(12):719-720. Le Tourneau C, Kurzrock R. PMID: 27725677.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    197. RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients. Clin Cancer Res. 2017 04 15; 23(8):1988-1997. Kato S, Subbiah V, Marchlik E, Elkin SK, Carter JL, Kurzrock R. PMID: 27683183.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    198. Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget. 2016 Sep 27; 7(39):64421-64430. Livingston JA, Hess KR, Naing A, Hong DS, Patel S, Benjamin RS, Ludwig JA, Conley A, Herzog CE, Anderson P, Meric-Bernstam F, Kurzrock R, Subbiah V. PMID: 27486883.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    199. Bringing Blood-Based Molecular Testing to the Clinic. Clin Cancer Res. 2016 Nov 15; 22(22):5400-5402. Janku F, Kurzrock R. PMID: 27663595.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    200. An appraisal of drug development timelines in the Era of precision oncology. Oncotarget. 2016 Aug 16; 7(33):53037-53046. Jardim DL, Schwaederle M, Hong DS, Kurzrock R. PMID: 27419632.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    201. An 84-Year-Old Woman With an Indolent B-Cell Lymphoma. Oncology (Williston Park). 2016 08 15; 30(8):705-8, 710, 712. Goodman AM, Choi M, Wang L, Kurzrock R. PMID: 27535668.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    202. Genomic Landscape of Malignant Mesotheliomas. Mol Cancer Ther. 2016 10; 15(10):2498-2507. Kato S, Tomson BN, Buys TP, Elkin SK, Carter JL, Kurzrock R. PMID: 27507853.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    203. TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. . 2016 10; 15(10):2475-2485. Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, Tsimberidou AM, Piha-Paul S, Anderson R, Ke D, Miller V, Yelensky R, Lee JJ, Hong D, Kurzrock R. PMID: 27466356.
      View in: PubMed   Mentions:
    204. Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013. Int J Cancer. 2016 Nov 01; 139(9):2135-41. Nikanjam M, Liu S, Kurzrock R. PMID: 27389805.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    205. ATM Mutations in Cancer: Therapeutic Implications. . 2016 08; 15(8):1781-91. Choi M, Kipps T, Kurzrock R. PMID: 27413114.
      View in: PubMed   Mentions:
    206. Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib. Cancer Chemother Pharmacol. 2016 Aug; 78(2):427-32. Lam LH, Capparelli EV, Kurzrock R. PMID: 27372908.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    207. Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors. Oncoscience. 2016; 3(5-6):164-72. Wheler JJ, Atkins JT, Janku F, Moulder SL, Stephens PJ, Yelensky R, Valero V, Miller V, Kurzrock R, Meric-Bernstam F. PMID: 27489863.
      View in: PubMed   Mentions:
    208. Universal Genomic Testing Needed to Win the War Against Cancer: Genomics IS the Diagnosis. JAMA Oncol. 2016 Jun 01; 2(6):719-20. Subbiah V, Kurzrock R. PMID: 27078832.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    209. Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design. Cancer Metastasis Rev. 2016 06; 35(2):263-75. Sicklick JK, Fanta PT, Shimabukuro K, Kurzrock R. PMID: 26857926.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    210. Health policy: The right to try is embodied in the right to die. Nat Rev Clin Oncol. 2016 07; 13(7):399-400. Cohen-Kurzrock BA, Cohen PR, Kurzrock R. PMID: 27217273.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    211. BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. . 2016 06; 15(6):1397-404. Janku F, Huang HJ, Claes B, Falchook GS, Fu S, Hong D, Ramzanali NM, Nitti G, Cabrilo G, Tsimberidou AM, Naing A, Piha-Paul SA, Wheler JJ, Karp DD, Holley VR, Zinner RG, Subbiah V, Luthra R, Kopetz S, Overman MJ, Kee BK, Patel S, Devogelaere B, Sablon E, Maertens G, Mills GB, Kurzrock R, Meric-Bernstam F. PMID: 27207774.
      View in: PubMed   Mentions:
    212. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. Cancer Res. 2016 07 01; 76(13):3690-701. Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, Tsimberidou AM, Piha-Paul S, Anderson R, Ke D, Miller V, Yelensky R, Lee JJ, Hong DS, Kurzrock R. PMID: 27197177.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCellsCTClinical Trials
    213. Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients. Clin Cancer Res. 2016 Nov 15; 22(22):5497-5505. Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, Patel SP, Harismendy O, Ikeda M, Parker BA, Kurzrock R. PMID: 27185373.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCTClinical Trials
    214. Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics. . 2016 07; 15(7):1682-90. Helsten T, Kato S, Schwaederle M, Tomson BN, Buys TP, Elkin SK, Carter JL, Kurzrock R. PMID: 27196769.
      View in: PubMed   Mentions:
    215. Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics. Oncotarget. 2016 Apr 26; 7(17):23454-67. Cohen PR, Tomson BN, Elkin SK, Marchlik E, Carter JL, Kurzrock R. PMID: 26981779.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    216. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget. 2016 Apr 26; 7(17):23227-38. Liu X, Kambrick S, Fu S, Naing A, Subbiah V, Blumenschein GR, Glisson BS, Kies MS, Tsimberidou AM, Wheler JJ, Zinner RG, Hong DS, Kurzrock R, Piha-Paul SA. PMID: 26933802.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    217. Merkel cell polyomavirus and human papilloma virus in proliferative skin lesions arising in patients treated with BRAF inhibitors. Arch Dermatol Res. 2016 Jul; 308(5):357-65. Falchook GS, Rady P, Konopinski JC, Busaidy N, Hess K, Hymes S, Nguyen HP, Prieto VG, Bustinza-Linares E, Lin Q, Parkhurst KL, Hong DS, Sherman S, Tyring SK, Kurzrock R. PMID: 27098388.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    218. Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. Cancer Chemother Pharmacol. 2016 05; 77(5):1097-102. Said R, Kakadiaris E, Piha-Paul S, Fu S, Falchook G, Janku F, Wheler JJ, Zinner R, Hong DS, Kurzrock R, Tsimberidou AM. PMID: 27085994.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    219. The effects of curcumin (diferuloylmethane) on body composition of patients with advanced pancreatic cancer. Oncotarget. 2016 Apr 12; 7(15):20293-304. Parsons HA, Baracos VE, Hong DS, Abbruzzese J, Bruera E, Kurzrock R. PMID: 26934122.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    220. My personal experiences at the BEST Medical Center: A day in the clinic-the morning. Clin Dermatol. 2016 May-Jun; 34(3):422-5. Cohen PR, Kurzrock R. PMID: 27265082.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    221. My personal experiences at the BEST Medical Center: A day in the clinic-the afternoon. Clin Dermatol. 2016 Jul-Aug; 34(4):517-20. Cohen PR, Kurzrock R. PMID: 27343967.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    222. The Conundrum of Genetic "Drivers" in Benign Conditions. J Natl Cancer Inst. 2016 08; 108(8). Kato S, Lippman SM, Flaherty KT, Kurzrock R. PMID: 27059373.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    223. Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. J Clin Oncol. 2016 05 20; 34(15):1764-71. Hong D, Infante J, Janku F, Jones S, Nguyen LM, Burris H, Naing A, Bauer TM, Piha-Paul S, Johnson FM, Kurzrock R, Golden L, Hynes S, Lin J, Lin AB, Bendell J. PMID: 27044938.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCTClinical Trials
    224. Erratum to: Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases. Cancer Chemother Pharmacol. 2016 Apr; 77(4):881. Fu S, Culotta KS, Falchook GS, Hong DS, Myers AL, Zhang YP, Naing A, Janku F, Hou MM, Kurzrock R. PMID: 26994910.
      View in: PubMed   Mentions: 1     Fields:    
    225. Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm. . 2016 04; 15(4):533-47. Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock R. PMID: 27009213.
      View in: PubMed   Mentions:
    226. Idiopathic multicentric Castleman's disease: a systematic literature review. Lancet Haematol. 2016 Apr; 3(4):e163-75. Liu AY, Nabel CS, Finkelman BS, Ruth JR, Kurzrock R, van Rhee F, Krymskaya VP, Kelleher D, Rubenstein AH, Fajgenbaum DC. PMID: 27063975.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCells
    227. Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers. Oncotarget. 2016 Mar 08; 7(10):11310-20. Liu S, Nikanjam M, Kurzrock R. PMID: 26824502.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    228. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget. 2016 Mar 01; 7(9):9707-17. Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, Banks KC, Lanman RB, Talasaz A, Parker BA, Kurzrock R. PMID: 26848768.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCells
    229. Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors. Drugs R D. 2016 Mar; 16(1):45-52. Falchook GS, Zhou X, Venkatakrishnan K, Kurzrock R, Mahalingam D, Goldman JW, Jung J, Ullmann CD, Milch C, Rosen LS, Sarantopoulos J. PMID: 26689566.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    230. Response. J Natl Cancer Inst. 2016 Mar; 108(3):djw001. Jardim DL, Schwaederle M, Lee JJ, Wei C, Mendelsohn J, Schilsky RL, Kurzrock R. PMID: 26912651.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    231. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. . 2016 04; 15(4):743-52. Schwaederle M, Parker BA, Schwab RB, Daniels GA, Piccioni DE, Kesari S, Helsten TL, Bazhenova LA, Romero J, Fanta PT, Lippman SM, Kurzrock R. PMID: 26873727.
      View in: PubMed   Mentions:
    232. Click chemistry, 3D-printing, and omics: the future of drug development. Oncotarget. 2016 Jan 19; 7(3):2155-8. Kurzrock R, Stewart DJ. PMID: 26734837.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    233. Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases. Cancer Chemother Pharmacol. 2016 Feb; 77(2):357-64. Siqing F, Culotta KS, Falchook GS, Hong DS, Myers AL, Zhang YP, Naing A, Janku F, Hou MM, Kurzrock R. PMID: 26698868.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    234. Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma. Oncotarget. 2015 Dec 15; 6(40):43127-34. Hong DS, Kurzrock R, Falchook GS, Andresen C, Kwak J, Ren M, Xu L, George GC, Kim KB, Nguyen LM, O'Brien JP, Nemunaitis J. PMID: 26503473.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    235. Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease. Immunotherapy. 2016; 8(1):17-26. Fajgenbaum DC, Kurzrock R. PMID: 26634298.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    236. Precision medicine: lessons learned from the SHIVA trial. Lancet Oncol. 2015 Dec; 16(16):e579-80. Tsimberidou AM, Kurzrock R. PMID: 26678197.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    237. Expression of estrogen and progesterone receptors across human malignancies: new therapeutic opportunities. Cancer Metastasis Rev. 2015 Dec; 34(4):547-61. PMID: 25543191.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    238. First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clin Cancer Res. 2016 Apr 15; 22(8):1932-9. Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R. PMID: 26603258.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    239. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med. 2015 Nov 18; 7(314):314ra185. Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MV, Mohseni M, Lawson D, Reimer C, Blakey DC, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR. PMID: 26582900.
      View in: PubMed   Mentions: 108     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    240. NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys. J Natl Compr Canc Netw. 2015 Nov; 13(11):1337-46. Kurzrock R, Colevas AD, Olszanski A, Akerley W, Arteaga CL, Carson WE, Clark JW, DiPersio JF, Ettinger DS, Morgan RJ, Schwartzberg LS, Venook AP, Gocke CD, Tait J, Stewart FM. PMID: 26553764.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    241. Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. Oncotarget. 2015 Oct 20; 6(32):32602-9. Patel SP, Schwaederle M, Daniels GA, Fanta PT, Schwab RB, Shimabukuro KA, Kesari S, Piccioni DE, Bazhenova LA, Helsten TL, Lippman SM, Parker BA, Kurzrock R. PMID: 26418953.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    242. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. BMC Cancer. 2015 Oct 16; 15:713. Liu X, George GC, Tsimberidou AM, Naing A, Wheler JJ, Kopetz S, Fu S, Piha-Paul SA, Eng C, Falchook GS, Janku F, Garrett C, Karp D, Kurzrock R, Zinner R, Raghav K, Subbiah V, Hess K, Meric-Bernstam F, Hong DS, Overman MJ. PMID: 26474549.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    243. The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases. Clin Cancer Res. 2015 Oct 15; 21(20):4561-8. Stewart DJ, Batist G, Kantarjian HM, Bradford JP, Schiller JH, Kurzrock R. PMID: 26473192.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    244. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. Oncotarget. 2015 Oct 06; 6(30):30408-19. van Rhee F, Casper C, Voorhees PM, Fayad LE, van de Velde H, Vermeulen J, Qin X, Qi M, Tromp B, Kurzrock R. PMID: 26327301.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    245. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget. 2015 Sep 29; 6(29):26886-94. Janku F, Claes B, Huang HJ, Falchook GS, Devogelaere B, Kockx M, Bempt IV, Reijans M, Naing A, Fu S, Piha-Paul SA, Hong DS, Holley VR, Tsimberidou AM, Stepanek VM, Patel SP, Kopetz ES, Subbiah V, Wheler JJ, Zinner RG, Karp DD, Luthra R, Roy-Chowdhuri S, Sablon E, Meric-Bernstam F, Maertens G, Kurzrock R. PMID: 26330075.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    246. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. Oncotarget. 2015 Sep 29; 6(29):28453-62. Subbiah IM, Falchook GS, Kaseb AO, Hess KR, Tsimberidou AM, Fu S, Subbiah V, Hong DS, Naing A, Piha-Paul SA, Akmal O, Janku F, Kurzrock R. PMID: 26164085.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    247. Understanding Toxicities of Targeted Agents: Implications for Anti-tumor Activity and Management. Semin Oncol. 2015 Dec; 42(6):863-75. Liu S, Kurzrock R. PMID: 26615131.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    248. Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress. Semin Oncol. 2015 Dec; 42(6):832-48. Falchook GS, Bastida CC, Kurzrock R. PMID: 26615129.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    249. Targeted Inhibitors: Novel Strategies for Response Optimization. Semin Oncol. 2015 Dec; 42(6):773-4. Kurzrock R. PMID: 26615124.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    250. Genomic landscape of salivary gland tumors. Oncotarget. 2015 Sep 22; 6(28):25631-45. Kato S, Elkin SK, Schwaederle M, Tomson BN, Helsten T, Carter JL, Kurzrock R. PMID: 26247885.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    251. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J Clin Oncol. 2015 Dec 01; 33(34):4023-31. Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S. PMID: 26392102.
      View in: PubMed   Mentions: 132     Fields:    Translation:HumansAnimalsCTClinical Trials
    252. The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing. Clin Cancer Res. 2016 Jan 01; 22(1):259-67. Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. PMID: 26373574.
      View in: PubMed   Mentions: 107     Fields:    Translation:Humans
    253. Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. J Natl Cancer Inst. 2015 Nov; 107(11). Jardim DL, Fontes Jardim DL, Schwaederle M, Wei C, Lee JJ, Hong DS, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R. PMID: 26378224.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    254. Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 2015 Sep 15; 6(27):24581. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. PMID: 26405159.
      View in: PubMed   Mentions:    Fields:    
    255. Actionability and precision oncology. Oncoscience. 2015; 2(10):779-80. Schwaederle M, Kurzrock R. PMID: 26682241.
      View in: PubMed   Mentions:
    256. Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications. Cancer Metastasis Rev. 2015 Sep; 34(3):479-96. Helsten T, Schwaederle M, Kurzrock R. PMID: 26224133.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    257. Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. J Clin Oncol. 2015 Nov 10; 33(32):3817-25. Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R. PMID: 26304871.
      View in: PubMed   Mentions: 100     Fields:    Translation:Humans
    258. Breast Cancer Experience of the Molecular Tumor Board at the University of California, San Diego Moores Cancer Center. J Oncol Pract. 2015 Nov; 11(6):442-9. Parker BA, Schwaederlé M, Scur MD, Boles SG, Helsten T, Subramanian R, Schwab RB, Kurzrock R. PMID: 26243651.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    259. A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. Oncotarget. 2015 Jul 30; 6(21):18693-706. Hong DS, Rosen P, Lockhart AC, Fu S, Janku F, Kurzrock R, Khan R, Amore B, Caudillo I, Deng H, Hwang YC, Loberg R, Ngarmchamnanrith G, Beaupre DM, Lee P. PMID: 26155941.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    260. A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors. Cancer Chemother Pharmacol. 2015 Sep; 76(3):597-603. Henary H, George GC, Wheler J, Naing A, Piha-Paul S, Fu S, Mistry R, Zinner R, Kurzrock R, Hong DS. PMID: 26210681.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    261. Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma. Clin Cancer Res. 2015 Nov 01; 21(21):4801-10. Hong DS, Kurzrock R, Wheler JJ, Naing A, Falchook GS, Fu S, Kim KB, Davies MA, Nguyen LM, George GC, Xu L, Shumaker R, Ren M, Mink J, Bedell C, Andresen C, Sachdev P, O'Brien JP, Nemunaitis J. PMID: 26169970.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    262. The National Clinical Trials Network: Conducting Successful Clinical Trials of New Therapies for Rare Cancers. Semin Oncol. 2015 Oct; 42(5):731-9. Schott AF, Welch JJ, Verschraegen CF, Kurzrock R. PMID: 26433554.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    263. Molecular landscape of prostate cancer: implications for current clinical trials. Cancer Treat Rev. 2015 Nov; 41(9):761-6. Khemlina G, Ikeda S, Kurzrock R. PMID: 26210103.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimals
    264. Genomic Profiling of Cancers of Unknown Primary Site: The Next Steps. JAMA Oncol. 2015 Jul; 1(4):542. Cobain EF, Chinnaiyan AM, Kurzrock R, Baker LH. PMID: 26181268.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    265. Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors. Int J Clin Pharmacol Ther. 2015 Jul; 53(7):563-72. Falchook GS, Venkatakrishnan K, Sarantopoulos J, Kurzrock R, Mita AC, Fu S, Mita MM, Zhou X, Jung JA, Ullmann CD, Milch C, Rosen LS. PMID: 26073352.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    266. Challenges and perspective of drug repurposing strategies in early phase clinical trials. Oncoscience. 2015; 2(6):576-80. Kato S, Moulder SL, Ueno NT, Wheler JJ, Meric-Bernstam F, Kurzrock R, Janku F. PMID: 26244164.
      View in: PubMed   Mentions:
    267. Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma. Cancer Treat Rev. 2015 Sep; 41(8):699-706. Ikeda S, Hansel DE, Kurzrock R. PMID: 26138514.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    268. A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. Oncotarget. 2015 Jun 10; 6(16):14139-52. Lazar V, Rubin E, Depil S, Pawitan Y, Martini JF, Gomez-Navarro J, Yver A, Kan Z, Dry JR, Kehren J, Validire P, Rodon J, Vielh P, Ducreux M, Galbraith S, Lehnert M, Onn A, Berger R, Pierotti MA, Porgador A, Pramesh CS, Ye DW, Carvalho AL, Batist G, Le Chevalier T, Morice P, Besse B, Vassal G, Mortlock A, Hansson J, Berindan-Neagoe I, Dann R, Haspel J, Irimie A, Laderman S, Nechushtan H, Al Omari AS, Haywood T, Bresson C, Soo KC, Osman I, Mata H, Lee JJ, Jhaveri K, Meurice G, Palmer G, Lacroix L, Koscielny S, Eterovic KA, Blay JY, Buller R, Eggermont A, Schilsky RL, Mendelsohn J, Soria JC, Rothenberg M, Scoazec JY, Hong WK, Kurzrock R. PMID: 25944621.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    269. The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab. Oncologist. 2015 Jul; 20(7):737-41. Busaidy NL, LoRusso P, Lawhorn K, Hess KR, Habra MA, Fu S, Hong DS, Chen HX, Doyle LA, Kurzrock R, Naing A. PMID: 26054632.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    270. Squamousness: Next-generation sequencing reveals shared molecular features across squamous tumor types. . 2015; 14(14):2355-61. Schwaederle M, Elkin SK, Tomson BN, Carter JL, Kurzrock R. PMID: 26030731.
      View in: PubMed   Mentions:
    271. Multiple gene aberrations and breast cancer: lessons from super-responders. BMC Cancer. 2015 May 29; 15:442. Wheler JJ, Atkins JT, Janku F, Moulder SL, Yelensky R, Stephens PJ, Kurzrock R. PMID: 26021831.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    272. Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. Invest New Drugs. 2015 Aug; 33(4):911-20. Said R, Kurzrock R, Naing A, Hong DS, Fu S, Piha-Paul SA, Wheler JJ, Janku F, Kee BK, Bidyasar S, Lim J, Wallace M, Tsimberidou AM. PMID: 25990659.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    273. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 2015 May 20; 6(14):12809-21. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. PMID: 25980577.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    274. Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics. . 2015; 14(13):2121-8. Parish A, Schwaederle M, Daniels G, Piccioni D, Fanta P, Schwab R, Shimabukuro K, Parker BA, Helsten T, Kurzrock R. PMID: 25950492.
      View in: PubMed   Mentions:
    275. The checklist: BEST medical center employment requirements 2015. Clin Dermatol. 2015 Jul-Aug; 33(4):493-7. Cohen PR, Kurzrock R. PMID: 26051067.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    276. Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. Invest New Drugs. 2015 Jun; 33(3):700-9. Rodrigues HV, Ke D, Lim J, Stephen B, Bellido J, Janku F, Zinner R, Tsimberidou A, Hong D, Piha-Paul S, Fu S, Naing A, Subbiah V, Karp D, Falchook G, Kurzrock R, Wheler J. PMID: 25902899.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    277. Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. Ann Oncol. 2015 Aug; 26(8):1791-8. Rodon J, Soria JC, Berger R, Batist G, Tsimberidou A, Bresson C, Lee JJ, Rubin E, Onn A, Schilsky RL, Miller WH, Eggermont AM, Mendelsohn J, Lazar V, Kurzrock R. PMID: 25908602.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    278. Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer. Ann Oncol. 2015 Jul; 26(7):1346-52. Moulder S, Helgason T, Janku F, Wheler J, Moroney J, Booser D, Albarracin C, Morrow PK, Atkins J, Koenig K, Gilcrease M, Kurzrock R. PMID: 25878190.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    279. Merkel Cell Carcinoma with a Suppressor of Fused (SUFU) Mutation: Case Report and Potential Therapeutic Implications. Dermatol Ther (Heidelb). 2015 Jun; 5(2):129-43. Cohen PR, Kurzrock R. PMID: 25876211.
      View in: PubMed   Mentions:
    280. On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients. . 2015 Jun; 14(6):1488-94. Schwaederle M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R. PMID: 25852059.
      View in: PubMed   Mentions:
    281. Meir Wetzler, MD. Cancer. 2015 Jul 01; 121(13):2106-7. Kurzrock R, Estrov Z, Talpaz M, Kantarjian HM. PMID: 25832851.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    282. Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. Invest New Drugs. 2015 Jun; 33(3):621-31. Hong DS, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R. PMID: 25822109.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    283. Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer. Oncotarget. 2015 Mar 20; 6(8):6029-39. Tsigelny IF, Wheler JJ, Greenberg JP, Kouznetsova VL, Stewart DJ, Bazhenova L, Kurzrock R. PMID: 25760241.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    284. Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. Clin Epigenetics. 2015; 7:29. Tsimberidou AM, Said R, Culotta K, Wistuba I, Jelinek J, Fu S, Falchook G, Naing A, Piha-Paul S, Zinner R, Siddik ZH, He G, Hess K, Stewart DJ, Kurzrock R, Issa JP. PMID: 25806091.
      View in: PubMed   Mentions: 7     Fields:    
    285. Molecular landscape of pancreatic cancer: implications for current clinical trials. Oncotarget. 2015 Mar 10; 6(7):4553-61. Heestand GM, Kurzrock R. PMID: 25714017.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    286. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev. 2015 Mar; 34(1):157-64. Yan M, Schwaederle M, Arguello D, Millis SZ, Gatalica Z, Kurzrock R. PMID: 25712293.
      View in: PubMed   Mentions: 74     Fields:    Translation:Humans
    287. Castleman's disease and sarcoidosis, a rare association resulting in a "mixed" response: a case report. J Med Case Rep. 2015 Feb 28; 9:45. Mohammed A, Janku F, Qi M, Kurzrock R. PMID: 25884809.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    288. Cyclin alterations in diverse cancers: Outcome and co-amplification network. Oncotarget. 2015 Feb 20; 6(5):3033-42. PMID: 25596748.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    289. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. . 2015 Apr; 14(4):847-56. Patel SP, Kurzrock R. PMID: 25695955.
      View in: PubMed   Mentions:
    290. Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. BMC Cancer. 2015 Feb 18; 15:61. Wheler J, Yelensky R, Falchook G, Kim KB, Hwu P, Tsimberidou AM, Stephens PJ, Hong D, Cronin MT, Kurzrock R. PMID: 25886620.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    291. SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. J Natl Cancer Inst. 2015 Mar; 107(3). Gonzalez-Angulo AM, Krop I, Akcakanat A, Chen H, Liu S, Li Y, Culotta KS, Tarco E, Piha-Paul S, Moulder-Thompson S, Velez-Bravo V, Sahin AA, Doyle LA, Do KA, Winer EP, Mills GB, Kurzrock R, Meric-Bernstam F. PMID: 25688104.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    292. Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines. Support Care Cancer. 2015 Sep; 23(9):2649-54. Naing A, Dalal S, Abdelrahim M, Wheler J, Hess K, Fu S, Hong DS, Janku F, Falchook GS, Ilustre A, Ouyang F, Kurzrock R. PMID: 25680763.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    293. VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy. Cancer Res. 2015 Apr 01; 75(7):1187-90. Schwaederlé M, Lazar V, Validire P, Hansson J, Lacroix L, Soria JC, Pawitan Y, Kurzrock R. PMID: 25672981.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    294. Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Ann Oncol. 2015 May; 26(5):1012-1018. Fu S, Hou MM, Naing A, Janku F, Hess K, Zinner R, Subbiah V, Hong D, Wheler J, Piha-Paul S, Tsimberidou A, Karp D, Araujo D, Kee B, Hwu P, Wolff R, Kurzrock R, Meric-Bernstam F. PMID: 25669829.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCellsCTClinical Trials
    295. Phase I trial of valproic acid and lenalidomide in patients with advanced cancer. Cancer Chemother Pharmacol. 2015 Apr; 75(4):869-74. Bilen MA, Fu S, Falchook GS, Ng CS, Wheler JJ, Abdelrahim M, Erguvan-Dogan B, Hong DS, Tsimberidou AM, Kurzrock R, Naing A. PMID: 25666183.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    296. Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome. Discov Med. 2015 Feb; 19(103):109-16. Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V. PMID: 25725225.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    297. Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathies. Discov Med. 2015 Feb; 19(103):101-8. PMID: 25725224.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    298. Androgen receptors beyond prostate cancer: an old marker as a new target. Oncotarget. 2015 Jan 20; 6(2):592-603. Munoz J, Wheler JJ, Kurzrock R. PMID: 25595907.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimals
    299. Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics. . 2015; 14(8):1252-9. Kato S, Schwaederle M, Daniels GA, Piccioni D, Kesari S, Bazhenova L, Shimabukuro K, Parker BA, Fanta P, Kurzrock R. PMID: 25695927.
      View in: PubMed   Mentions:
    300. Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes. . 2015; 14(14):2219-21. Kurzrock R, Giles FJ. PMID: 26030337.
      View in: PubMed   Mentions:
    301. Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies. . 2015; 14(21):3434-40. Jain RK, Hong DS, Naing A, Wheler J, Helgason T, Shi NY, Gad Y, Kurzrock R. PMID: 26467427.
      View in: PubMed   Mentions:
    302. Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer. . 2015; 14(11):1730-7. Schwaederle M, Daniels GA, Piccioni DE, Kesari S, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R. PMID: 25928476.
      View in: PubMed   Mentions:
    303. VEGF and dual-EGFR inhibition in colorectal cancer. . 2015; 14(8):1129-30. Falchook GS, Kurzrock R. PMID: 25845022.
      View in: PubMed   Mentions:
    304. BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid. 2015 Jan; 25(1):71-7. PMID: 25285888.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    305. Promoting Precision Cancer Medicine through a Community-Driven Knowledgebase. J Pers Med. 2014 Dec 15; 4(4):475-88. Geifman N, Haviv I, Kurzrock R, Rubin E. PMID: 25563458.
      View in: PubMed   Mentions:
    306. Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome. Discov Med. 2014 Dec; 18(101):323-30. PMID: 25549703.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    307. Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome. Discov Med. 2014 Dec; 18(101):331-9. Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V. PMID: 25549704.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    308. Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art. Cancer Metastasis Rev. 2014 Dec; 33(4):1109-24. Randall JM, Millard F, Kurzrock R. PMID: 25365943.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    309. Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. Oncotarget. 2014 Nov 30; 5(22):11168-79. PMID: 25426553.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    310. A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours. Oncotarget. 2014 Nov 30; 5(22):11154-67. PMID: 25525888.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    311. Targeting hypoxia-inducible factor-1a (HIF-1a) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. Oncotarget. 2014 Nov 15; 5(21):10280-92. Falchook GS, Wheler JJ, Naing A, Jackson EF, Janku F, Hong D, Ng CS, Tannir NM, Lawhorn KN, Huang M, Angelo LS, Vishwamitra D, Hess K, Howard AN, Parkhurst KL, Amin HM, Kurzrock R. PMID: 25373733.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    312. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. Invest New Drugs. 2015 Feb; 33(1):215-24. Falchook GS, Wheler JJ, Naing A, Piha-Paul SA, Fu S, Tsimberidou AM, Hong DS, Janku F, Zinner R, Jiang Y, Huang M, Lin Q, Parkhurst K, Kurzrock R. PMID: 25363205.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    313. NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies. J Natl Compr Canc Netw. 2014 Nov; 12(11):1629-49. PMID: 25361808.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    314. A framework for genomic biomarker actionability and its use in clinical decision making. Oncoscience. 2014; 1(10):614-623. Vidwans SJ, Turski ML, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock R. PMID: 25593991.
      View in: PubMed   Mentions:
    315. A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. Invest New Drugs. 2015 Feb; 33(1):177-86. Falchook GS, Moulder S, Naing A, Wheler JJ, Hong DS, Piha-Paul SA, Tsimberidou AM, Fu S, Zinner R, Janku F, Jiang Y, Huang M, Parkhurst KL, Kurzrock R. PMID: 25323060.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    316. Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. Clin Cancer Res. 2014 Dec 15; 20(24):6336-45. PMID: 25326232.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    317. Unique molecular landscapes in cancer: implications for individualized, curated drug combinations. Cancer Res. 2014 Dec 15; 74(24):7181-4. Wheler J, Lee JJ, Kurzrock R. PMID: 25326492.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    318. Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. Cancer Discov. 2015 Jan; 5(1):64-71. Hyman DM, Diamond EL, Vibat CR, Hassaine L, Poole JC, Patel M, Holley VR, Cabrilo G, Lu TT, Arcila ME, Chung YR, Rampal R, Lacouture ME, Rosen N, Meric-Bernstam F, Baselga J, Kurzrock R, Erlander MG, Janku F, Abdel-Wahab O. PMID: 25324352.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    319. Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. Oncotarget. 2014 Oct 15; 5(19):8937-46. Said R, Ye Y, Falchook GS, Janku F, Naing A, Zinner R, Blumenschein GR, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Kurzrock R, Palmer GA, Aldape K, Hess KR, Tsimberidou AM. PMID: 25313136.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    320. Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic. Clin Cancer Res. 2014 Dec 01; 20(23):5956-63. Tang C, Hess K, Jardim DL, Gagliato Dde M, Tsimberidou AM, Falchook G, Fu S, Janku F, Naing A, Piha-Paul S, Subbiah V, Wheler J, Zinner RG, Kurzrock R, Ellis LM, Meric-Berstam F, Hong DS. PMID: 25316815.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    321. Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. . 2014 Dec; 13(12):3175-84. Ganesan P, Moulder S, Lee JJ, Janku F, Valero V, Zinner RG, Naing A, Fu S, Tsimberidou AM, Hong D, Stephen B, Stephens P, Yelensky R, Meric-Bernstam F, Kurzrock R, Wheler JJ. PMID: 25253784.
      View in: PubMed   Mentions:
    322. Novel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumors. PLoS One. 2014; 9(8):e93676. PMID: 25119929.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    323. Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer. Oncoscience. 2014; 1(8):540-9. Falchook GS, Naing A, Wheler JJ, Tsimberidou AM, Zinner R, Hong DS, Fu S, Piha-Paul SA, Janku F, Hess KR, Bastida C, Kurzrock R. PMID: 25594061.
      View in: PubMed   Mentions:
    324. Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experience. Oncoscience. 2014 Jul 27; 1(7):522-530. Corrales-Medina FF, Herzog C, Hess K, Egas-Bejar D, Hong DS, Falchook G, Anderson P, Nunez C, Huh WW, Naing A, Tsimberidou AM, Wheler J, Paul SP, Janku F, Kleinerman ES, Kurzrock R, Subbiah V. PMID: 25587555.
      View in: PubMed   Mentions:
    325. MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors. Clin Genitourin Cancer. 2015 Feb; 13(1):e19-26. PMID: 25087088.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    326. Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples. Clin Epigenetics. 2014; 6(1):13. PMID: 25024751.
      View in: PubMed   Mentions: 4     Fields:    
    327. Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. Clin Cancer Res. 2014 Sep 15; 20(18):4827-36. Tsimberidou AM, Wen S, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Aldape K, Ye Y, Kurzrock R, Berry D. PMID: 24987059.
      View in: PubMed   Mentions: 72     Fields:    Translation:Humans
    328. Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res. 2014 Sep 01; 20(17):4449-58. PMID: 24958809.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    329. Characteristics and survival of patients with advanced cancer and p53 mutations. Oncotarget. 2014 Jun 15; 5(11):3871-9. PMID: 25003695.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    330. BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease. Oncotarget. 2014 Jun 15; 5(11):3607-10. Janku F, Vibat CR, Kosco K, Holley VR, Cabrilo G, Meric-Bernstam F, Stepanek VM, Lin PP, Leppin L, Hassaine L, Poole JC, Kurzrock R, Erlander MG. PMID: 25003820.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    331. First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors. Invest New Drugs. 2014 Dec; 32(6):1204-12. Hong DS, Henary H, Falchook GS, Naing A, Fu S, Moulder S, Wheler JJ, Tsimberidou A, Durand JB, Khan R, Yang P, Johansen M, Newman RA, Kurzrock R. PMID: 24919855.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    332. Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study. Invest New Drugs. 2014 Dec; 32(6):1181-7. PMID: 24879333.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    333. Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. Oncotarget. 2014 May 30; 5(10):3029-38. PMID: 24912489.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCellsCTClinical Trials
    334. Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. Oncotarget. 2014 May 30; 5(10):3012-22. PMID: 24931142.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCells
    335. Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms. Cancer Treat Rev. 2014 Aug; 40(7):883-91. Liu S, Kurzrock R. PMID: 24867380.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansAnimals
    336. Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. Oncotarget. 2014 May 15; 5(9):2349-54. PMID: 24811890.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    337. Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul; 74(1):125-30. Bendell JC, Hong DS, Burris HA, Naing A, Jones SF, Falchook G, Bricmont P, Elekes A, Rock EP, Kurzrock R. PMID: 24819685.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCTClinical Trials
    338. Erdheim-Chester disease: characteristics and management. Mayo Clin Proc. 2014 Jul; 89(7):985-96. PMID: 24814521.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    339. Molecular tumor board: the University of California-San Diego Moores Cancer Center experience. Oncologist. 2014 Jun; 19(6):631-6. PMID: 24797821.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    340. Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program. Anticancer Res. 2014 May; 34(5):2349-55. PMID: 24778042.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    341. Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy. Invest New Drugs. 2014 Aug; 32(4):717-22. PMID: 24764123.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    342. MABp1, a first-in-class true human antibody targeting interleukin-1a in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol. 2014 May; 15(6):656-66. PMID: 24746841.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCTClinical Trials
    343. Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer. 2014 Jul 15; 120(14):2164-73. PMID: 24752867.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCellsCTClinical Trials
    344. MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget. 2014 Apr 15; 5(7):1837-45. Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, Subbiah V, Piha-Paul SA, Fu S, Murphy MB, Ajani J, Tang C, Hess K, Hamilton SR, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. PMID: 24742823.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    345. Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus. Oncotarget. 2014 Apr 15; 5(7):1846-55. PMID: 24742900.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    346. U.S. Food and Drug Administration inspections of clinical investigators: overview of results from 1977 to 2009. Clin Cancer Res. 2014 Jul 01; 20(13):3364-70. PMID: 24737548.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    347. Pediatric patients with refractory central nervous system tumors: experiences of a clinical trial combining bevacizumab and temsirolimus. Anticancer Res. 2014 Apr; 34(4):1939-45. PMID: 24692729.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    348. Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response. Oncologist. 2014 Apr; 19(4):426-8. PMID: 24668327.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    349. HER2 aberrations in cancer: implications for therapy. Cancer Treat Rev. 2014 Jul; 40(6):770-80. PMID: 24656976.
      View in: PubMed   Mentions: 74     Fields:    Translation:HumansAnimalsCells
    350. A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res. 2014 Apr 15; 20(8):2192-204. PMID: 24563479.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    351. Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer. J Natl Compr Canc Netw. 2014 Feb; 12(2):194-203. PMID: 24586081.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    352. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemother Pharmacol. 2014 Mar; 73(3):495-501. PMID: 24435060.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    353. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep. 2014 Jan 30; 6(2):377-87. PMID: 24440717.
      View in: PubMed   Mentions: 93     Fields:    Translation:HumansCTClinical Trials
    354. NF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations. Oncotarget. 2014 Jan 15; 5(1):67-77. PMID: 24393766.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    355. Anakinra-responsive lichen planus in a woman with Erdheim-Chester disease: a therapeutic enigma. Dermatol Online J. 2014 Jan 15; 20(1):21241. PMID: 24456945.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    356. Imatinib-induced postoperative periorbital purpura: GASP (Gleevec-Associated Surgical Purpura) in a woman with imatinib-treated chronic myelogenous leukemia. Dermatol Online J. 2014 Jan 15; 20(1):21242. PMID: 24456946.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    357. Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors. Clin Epigenetics. 2014 Jan 09; 6(1):2. PMID: 24401732.
      View in: PubMed   Mentions: 5     Fields:    
    358. Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies. Cancer Chemother Pharmacol. 2014 Mar; 73(3):467-73. PMID: 24390424.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    359. A cancer trial scandal and its regulatory backlash. Nat Biotechnol. 2014 Jan; 32(1):27-31. PMID: 24406925.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    360. MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors. Oncoscience. 2014; 1(1):5-13. Tang C, Jardim DL, Falchook GS, Hess K, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, De Melo Galgiato D, Westin SN, Meric-Bernstam F, Kurzrock R, Hong DS. PMID: 25593979.
      View in: PubMed   Mentions:
    361. Retreatment after secondary resistance or mixed response: a pilot study. Oncology. 2013; 85(6):350-5. PMID: 24335388.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    362. Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies. Invest New Drugs. 2014 Jun; 32(3):465-72. PMID: 24306314.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    363. A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors. Invest New Drugs. 2014 Jun; 32(3):436-44. PMID: 24258465.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCellsCTClinical Trials
    364. A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2014 Jun; 12(3):167-177.e2. PMID: 24365125.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    365. Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugs. Clin Cancer Res. 2014 Jan 15; 20(2):281-8. PMID: 24190980.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    366. Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer. Ann Oncol. 2013 Dec; 24(12):3004-11. PMID: 24158411.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    367. Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unit. Oncologist. 2013; 18(12):1315-20. PMID: 24153239.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    368. Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment. Head Neck. 2014 Mar; 36(3):E25-7. PMID: 23852769.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    369. Transient severe hyperbilirubinemia after hepatic arterial infusion of oxaliplatin in patients with liver metastases. Cancer Chemother Pharmacol. 2013 Dec; 72(6):1265-71. PMID: 24101145.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    370. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. . 2013 Dec; 12(12):2857-63. PMID: 24092809.
      View in: PubMed   Mentions:
    371. Equipoise abandoned? Randomization and clinical trials. Ann Oncol. 2013 Oct; 24(10):2471-2474. PMID: 24072520.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    372. Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial. Clin Cancer Res. 2013 Oct 01; 19(19):5474-84. PMID: 24089446.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    373. Hepatic arterial infusion therapy in advanced cancer and liver-predominant disease: the MD Anderson Experience. Hepatogastroenterology. 2013 Oct; 60(127):1611-23. PMID: 24634931.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    374. Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528. Cancer Chemother Pharmacol. 2013 Nov; 72(5):1089-96. PMID: 24057042.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    375. Genetics on a WHIM. Br J Haematol. 2014 Jan; 164(1):15-23. PMID: 24111611.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimals
    376. Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations. . 2013 Oct; 12(10):2167-75. PMID: 23963360.
      View in: PubMed   Mentions:
    377. Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Invest New Drugs. 2013 Oct; 31(5):1192-200. PMID: 23907406.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCellsCTClinical Trials
    378. Morphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing's sarcoma (EWS/FLI1) and Wilms' tumor(WT1). PLoS One. 2013; 8(7):e68985. PMID: 23922674.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    379. A pilot study of temsirolimus and body composition. J Cachexia Sarcopenia Muscle. 2013 Dec; 4(4):259-65. PMID: 23893509.
      View in: PubMed   Mentions: 8     Fields:    
    380. Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors. Clin Cancer Res. 2013 Sep 01; 19(17):4824-31. PMID: 23873691.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    381. Body composition and survival in the early clinical trials setting. Eur J Cancer. 2013 Oct; 49(15):3068-75. PMID: 23867127.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    382. Effect of duration of scan acquisition on CT perfusion parameter values in primary and metastatic tumors in the lung. Eur J Radiol. 2013 Oct; 82(10):1811-8. PMID: 23769187.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    383. Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. Invest New Drugs. 2014 Apr; 32(2):279-86. PMID: 23756764.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    384. Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation. J Clin Oncol. 2013 Jul 10; 31(20):e351-2. PMID: 23733763.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    385. Posterior reversible encephalopathy syndrome: more than meets the eye. J Clin Oncol. 2013 Jul 10; 31(20):e360-3. PMID: 23733774.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    386. Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses. Oncotarget. 2013 Jun; 4(6):890-8. PMID: 23765114.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    387. Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications. Oncotarget. 2013 Jun; 4(6):884-9. PMID: 23800680.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    388. Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Ann Oncol. 2013 Sep; 24(9):2256-61. PMID: 23676418.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    389. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res. 2013 Jul 01; 19(13):3659-70. PMID: 23659971.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCTClinical Trials
    390. The Karabus affair speaks to larger issues for American academic and medical centers. Clin Dermatol. 2013 May-Jun; 31(3):325-6. PMID: 23608452.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    391. Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population. Oncotarget. 2013 May; 4(5):772-84. PMID: 23800712.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    392. P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget. 2013 May; 4(5):705-14. PMID: 23670029.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    393. RE: Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials. J Natl Cancer Inst. 2013 Jun 05; 105(11):833. PMID: 23628598.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    394. Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors. Invest New Drugs. 2014 Feb; 32(1):154-9. PMID: 23609829.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    395. Fool's gold, lost treasures, and the randomized clinical trial. BMC Cancer. 2013 Apr 16; 13:193. PMID: 23587187.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    396. Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes. Ann Oncol. 2013 Aug; 24(8):2158-65. PMID: 23576709.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    397. Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapy. J Cancer Res Clin Oncol. 2013 Jun; 139(6):963-70. PMID: 23455881.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    398. A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R) : implications for inhibition of the IGF-1R signal. Oncotarget. 2013 Mar; 4(3):463-73. PMID: 23531874.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    399. Compliance in early-phase cancer clinical trials research. Oncologist. 2013; 18(3):308-13. PMID: 23457001.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    400. Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib. JAMA Dermatol. 2013 Mar; 149(3):322-6. PMID: 23552670.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    401. Dodging a dogma: is treating beyond progression beneficial? Cancer Chemother Pharmacol. 2013 May; 71(5):1385-6. PMID: 23443308.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    402. A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies. Eur J Cancer. 2013 May; 49(7):1521-9. PMID: 23433846.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    403. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer. 2013 Mar 05; 108(4):826-30. PMID: 23412108.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCTClinical Trials
    404. Unilateral proptosis. JAMA. 2013 Feb 13; 309(6):605-6. PMID: 23403685.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    405. Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation. Target Oncol. 2013 Sep; 8(3):183-188. PMID: 23400451.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    406. Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment. J Thorac Oncol. 2013 Feb; 8(2):e19-20. PMID: 23328556.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    407. Effect of sampling frequency on perfusion values in perfusion CT of lung tumors. AJR Am J Roentgenol. 2013 Feb; 200(2):W155-62. PMID: 23345379.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    408. BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget. 2013 Feb; 4(2):310-5. PMID: 23470635.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    409. A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies. Invest New Drugs. 2013 Aug; 31(4):967-73. PMID: 23361621.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCellsCTClinical Trials
    410. Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway. J Clin Oncol. 2013 Mar 20; 31(9):e137-40. PMID: 23358976.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    411. Reply to A. Levy et al. J Clin Oncol. 2013 Jan 20; 31(3):396. PMID: 23451354.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    412. A tale of two histiocytic disorders. Oncologist. 2013; 18(1):2-4. PMID: 23299771.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    413. Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer. Oncotarget. 2013 Jan; 4(1):118-27. PMID: 23435217.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    414. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget. 2013 Jan; 4(1):156-65. PMID: 23391555.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    415. Molecular profiling and the reclassification of cancer: divide and conquer. Am Soc Clin Oncol Educ Book. 2013; 127-34. PMID: 23714478.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    416. Warning signal: unaware of an in absentia conviction, South African cancer specialist jailed on return to the United Arab Emirates. Clin Dermatol. 2013 Jan-Feb; 31(1):128-30. PMID: 23245984.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    417. Binding partners for curcumin in human schwannoma cells: biologic implications. Bioorg Med Chem. 2013 Feb 15; 21(4):932-9. PMID: 23294827.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    418. PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget. 2012 Dec; 3(12):1566-75. PMID: 23248156.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    419. It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy. . 2012 Dec; 11(12):2549-55. PMID: 23204432.
      View in: PubMed   Mentions:
    420. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer Treat Rev. 2013 Jun; 39(4):375-87. PMID: 23199899.
      View in: PubMed   Mentions: 72     Fields:    Translation:Humans
    421. A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. Invest New Drugs. 2013 Aug; 31(4):918-26. PMID: 23179336.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCellsCTClinical Trials
    422. Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver. Cancer Chemother Pharmacol. 2013 Feb; 71(2):389-97. PMID: 23143207.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    423. Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy. Ann Oncol. 2013 Mar; 24(3):838-42. PMID: 23139256.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    424. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res. 2013 Jan 01; 73(1):276-84. PMID: 23066039.
      View in: PubMed   Mentions: 111     Fields:    Translation:HumansCells
    425. Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009. Clin Cancer Res. 2012 Nov 15; 18(22):6356-63. PMID: 23014530.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    426. Targeted therapy in rare cancers--adopting the orphans. Nat Rev Clin Oncol. 2012 Nov; 9(11):631-42. PMID: 22965154.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    427. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res. 2012 Nov 15; 18(22):6373-83. PMID: 22966018.
      View in: PubMed   Mentions: 181     Fields:    Translation:Humans
    428. The "shield sign" in two men with metastatic salivary duct carcinoma to the skin: cutaneous metastases presenting as carcinoma hemorrhagiectoides. J Clin Aesthet Dermatol. 2012 Sep; 5(9):27-36. PMID: 23050032.
      View in: PubMed   Mentions:
    429. Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. Br J Cancer. 2012 Sep 25; 107(7):1093-9. PMID: 22935583.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
    430. Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Clin Cancer Res. 2012 Oct 15; 18(20):5796-805. PMID: 22927482.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    431. Mechanistic basis for overcoming platinum resistance using copper chelating agents. . 2012 Nov; 11(11):2483-94. PMID: 22914438.
      View in: PubMed   Mentions:
    432. Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist. . 2012 Nov; 11(11):2541-6. PMID: 22914439.
      View in: PubMed   Mentions:
    433. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 2012 Aug; 13(8):773-81. PMID: 22805291.
      View in: PubMed   Mentions: 152     Fields:    Translation:HumansCTClinical Trials
    434. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012 Aug; 13(8):782-9. PMID: 22805292.
      View in: PubMed   Mentions: 167     Fields:    Translation:HumansCTClinical Trials
    435. Advance care planning in patients with cancer referred to a phase I clinical trials program: the MD Anderson Cancer Center experience. J Clin Oncol. 2012 Aug 10; 30(23):2891-6. PMID: 22778314.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    436. Effect of dual vascular input functions on CT perfusion parameter values and reproducibility in liver tumors and normal liver. J Comput Assist Tomogr. 2012 Jul-Aug; 36(4):388-93. PMID: 22805665.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    437. Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs. Ann Oncol. 2012 Nov; 23(11):2960-2963. PMID: 22745218.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    438. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2012 Aug 01; 18(15):4173-82. PMID: 22693357.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansCTClinical Trials
    439. Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol. 2012 Jul 20; 30(21):2684-90. PMID: 22689801.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    440. Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies. Cancer. 2012 Dec 15; 118(24):6144-51. PMID: 22674635.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    441. Ewing's sarcoma: overcoming the therapeutic plateau. Discov Med. 2012 Jun; 13(73):405-15. PMID: 22742646.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    442. Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis. Hepatogastroenterology. 2012 Jun; 59(116):960-4. PMID: 22580643.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    443. Eyelash trichomegaly: review of congenital, acquired, and drug-associated etiologies for elongation of the eyelashes. Int J Dermatol. 2012 Jun; 51(6):631-46; quiz 643-4, 646. PMID: 22607279.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    444. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. PLoS One. 2012; 7(5):e38033. PMID: 22675430.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    445. A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin Cancer Res. 2012 Jun 15; 18(12):3396-406. PMID: 22634319.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansCTClinical Trials
    446. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012 May 19; 379(9829):1893-901. PMID: 22608338.
      View in: PubMed   Mentions: 276     Fields:    Translation:HumansCTClinical Trials
    447. Cutaneous Castleman disease. Br J Haematol. 2012 Jun; 157(6):652. PMID: 22533925.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    448. Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience. Clin Colorectal Cancer. 2012 Dec; 11(4):297-303. PMID: 22537607.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    449. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol. 2012 Jul 01; 30(19):2348-53. PMID: 22529266.
      View in: PubMed   Mentions: 99     Fields:    Translation:HumansCellsCTClinical Trials
    450. Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol Oncol. 2012 Jul; 126(1):47-53. PMID: 22487539.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    451. Overcoming platinum resistance through the use of a copper-lowering agent. . 2012 Jun; 11(6):1221-5. PMID: 22491798.
      View in: PubMed   Mentions:
    452. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res. 2012 May 01; 18(9):2625-31. PMID: 22465830.
      View in: PubMed   Mentions: 81     Fields:    Translation:HumansCTClinical Trials
    453. Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience. Clin Cancer Res. 2012 May 15; 18(10):2922-9. PMID: 22452943.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    454. Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience. Ann Oncol. 2012 Aug; 23(8):1963-1967. PMID: 22377564.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    455. BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res. 2012 Apr 15; 18(8):2326-35. PMID: 22355009.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCellsCTClinical Trials
    456. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012 Mar 10; 30(8):777-82. PMID: 22271473.
      View in: PubMed   Mentions: 188     Fields:    Translation:Humans
    457. Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy. Nutr Cancer. 2012; 64(2):206-17. PMID: 22229660.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    458. Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service. PLoS One. 2012; 7(1):e29330. PMID: 22235285.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    459. Treatment of chronic myelogenous leukemia as a paradigm for solid tumors: how targeted agents in newly diagnosed disease transformed outcomes. Am Soc Clin Oncol Educ Book. 2012; 179-85. PMID: 24451731.
      View in: PubMed   Mentions: 2     Fields:    
    460. Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies. Cancer Chemother Pharmacol. 2012 May; 69(5):1117-26. PMID: 22205203.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    461. Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. . 2012 Feb; 11(2):308-16. PMID: 22203732.
      View in: PubMed   Mentions:
    462. Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside. J Clin Oncol. 2012 Feb 10; 30(5):e64-8. PMID: 22203760.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    463. Anticoagulation-induced severe bleeding in a patient receiving bevacizumab therapy. Int J Hematol. 2012 Jan; 95(1):1-2. PMID: 22170230.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    464. BRAF mutations in advanced cancers: clinical characteristics and outcomes. PLoS One. 2011; 6(10):e25806. El-Osta H, Falchook G, Tsimberidou A, Hong D, Naing A, Kim K, Wen S, Janku F, Kurzrock R. PMID: 22039425.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    465. R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis. PLoS One. 2011; 6(10):e26060. Huang HJ, Angelo LS, Rodon J, Sun M, Kuenkele KP, Parsons HA, Trent JC, Kurzrock R. PMID: 22022506.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    466. Advancing the scope of nursing practice: hepatic arterial catheter removal. Clin J Oncol Nurs. 2011 Oct; 15(5):465-8. PMID: 21951733.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    467. Erdheim-Chester disease of the central nervous system: new manifestations of a rare disease. AJNR Am J Neuroradiol. 2011 Dec; 32(11):2126-31. PMID: 21960492.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    468. Insulin-like growth factor 1 receptor (IGF-1R) inhibitor: another arrow in the quiver - Will it hit the moving target? Expert Opin Investig Drugs. 2011 Nov; 20(11):1471-7. PMID: 21936711.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    469. Combining curcumin (diferuloylmethane) and heat shock protein inhibition for neurofibromatosis 2 treatment: analysis of response and resistance pathways. . 2011 Nov; 10(11):2094-103. PMID: 21903608.
      View in: PubMed   Mentions:
    470. A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin Cancer Res. 2011 Nov 01; 17(21):6840-6. Moroney JW, Schlumbrecht MP, Helgason T, Coleman RL, Moulder S, Naing A, Bodurka DC, Janku F, Hong DS, Kurzrock R. PMID: 21890452.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    471. Novel therapeutic targets in non-small cell lung cancer. J Thorac Oncol. 2011 Sep; 6(9):1601-12. PMID: 21849857.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    472. Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience. Oncologist. 2011; 16(9):1292-8. PMID: 21859821.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    473. Outcome analyses after the first admission to an intensive care unit in patients with advanced cancer referred to a phase I clinical trials program. J Clin Oncol. 2011 Sep 10; 29(26):3547-52. PMID: 21844494.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    474. Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus. J Clin Oncol. 2011 Sep 10; 29(26):e727-30. PMID: 21844496.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    475. A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res. 2011 Oct 15; 17(20):6582-91. Hong DS, Kurzrock R, Oh Y, Wheler J, Naing A, Brail L, Callies S, André V, Kadam SK, Nasir A, Holzer TR, Meric-Bernstam F, Fishman M, Simon G. PMID: 21831956.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCTClinical Trials
    476. Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. Cancer. 2012 Mar 01; 118(5):1422-8. Garrido-Laguna I, Janku F, Vaklavas C, Falchook GS, Fu S, Hong DS, Naing A, Tsimberidou AM, Wen S, Kurzrock R. PMID: 21823111.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    477. The inverted pyramid of biomarker-driven trials. Nat Rev Clin Oncol. 2011 08 02; 8(9):562-6. PMID: 21808269.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    478. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One. 2011; 6(7):e22769. PMID: 21829508.
      View in: PubMed   Mentions: 81     Fields:    Translation:Humans
    479. Reproducibility of CT perfusion parameters in liver tumors and normal liver. Radiology. 2011 Sep; 260(3):762-70. PMID: 21788525.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    480. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res. 2011 Sep 15; 17(18):6052-60. Naing A, Kurzrock R, Burger A, Gupta S, Lei X, Busaidy N, Hong D, Chen HX, Doyle LA, Heilbrun LK, Rohren E, Ng C, Chandhasin C, LoRusso P. PMID: 21750201.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCTClinical Trials
    481. Phase 1 clinical trials for sarcomas: the cutting edge. Curr Opin Oncol. 2011 Jul; 23(4):352-60. Subbiah V, Kurzrock R. PMID: 21519259.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    482. Reproducibility of perfusion parameters obtained from perfusion CT in lung tumors. AJR Am J Roentgenol. 2011 Jul; 197(1):113-21. PMID: 21701018.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    483. Transformation of human mesenchymal cells and skin fibroblasts into hematopoietic cells. PLoS One. 2011; 6(6):e21250. Harris DM, Hazan-Haley I, Coombes K, Bueso-Ramos C, Liu J, Liu Z, Li P, Ravoori M, Abruzzo L, Han L, Singh S, Sun M, Kundra V, Kurzrock R, Estrov Z. PMID: 21731684.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    484. A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2012 Jan; 69(1):165-72. PMID: 21638123.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    485. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 01; 29(19):2660-6. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Müller T, Ratain MJ, Salgia R. PMID: 21606412.
      View in: PubMed   Mentions: 164     Fields:    Translation:HumansCTClinical Trials
    486. Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol. 2011 May 17; 8(9):528-39. PMID: 21587219.
      View in: PubMed   Mentions: 266     Fields:    Translation:HumansAnimalsCells
    487. Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity. . 2011 Jul; 10(7):1300-7. PMID: 21571911.
      View in: PubMed   Mentions:
    488. Prevalence of complementary medicine use in a phase 1 clinical trials program: the MD Anderson Cancer Center Experience. Cancer. 2011 Nov 15; 117(22):5142-50. PMID: 21538342.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    489. Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer. Cancer Chemother Pharmacol. 2011 Dec; 68(6):1507-16. Tsimberidou AM, Lewis N, Reid T, Burris H, Urban P, Tan EY, Anand S, Uehara C, Kurzrock R. PMID: 21499896.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    490. Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer. J Clin Oncol. 2011 Jul 01; 29(19):e572-5. Moulder S, Moroney J, Helgason T, Wheler J, Booser D, Albarracin C, Morrow PK, Koenig K, Kurzrock R. PMID: 21482991.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    491. Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures. PLoS One. 2011 Apr 06; 6(4):e18424. PMID: 21494688.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCells
    492. Castleman's disease: from basic mechanisms to molecular therapeutics. Oncologist. 2011; 16(4):497-511. PMID: 21441298.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCells
    493. Phase I clinical trial outcomes in 93 patients with brain metastases: the MD anderson cancer center experience. Clin Cancer Res. 2011 Jun 15; 17(12):4110-8. Tsimberidou AM, Letourneau K, Wen S, Wheler J, Hong D, Naing A, Iskander NG, Uehara C, Kurzrock R. PMID: 21415223.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    494. Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic. Oncologist. 2011; 16(3):327-35. PMID: 21339262.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    495. Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors. J Cancer. 2011 Feb 10; 2:81-9. Naing A, Reuben JM, Camacho LH, Gao H, Lee BN, Cohen EN, Verschraegen C, Stephen S, Aaron J, Hong D, Wheler J, Kurzrock R. PMID: 21326629.
      View in: PubMed   Mentions:
    496. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab. 2011 Apr; 96(4):997-1005. Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Busaidy NL, Waguespack SG, Hernandez M, El Naggar AK, El Naggar AK, Bidyasar S, Wright J, Sherman SI, Kurzrock R. PMID: 21289252.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCellsCTClinical Trials
    497. Cetuximab-associated elongation of the eyelashes: case report and review of eyelash trichomegaly secondary to epidermal growth factor receptor inhibitors. Am J Clin Dermatol. 2011 Feb 01; 12(1):63-7. Cohen PR, Escudier SM, Kurzrock R. PMID: 20726623.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    498. Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus) -based treatment. J Clin Oncol. 2011 Apr 20; 29(12):e333-5. Piha-Paul SA, Hong DS, Kurzrock R. PMID: 21263090.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    499. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. . 2011 Mar; 10(3):558-65. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R. PMID: 21216929.
      View in: PubMed   Mentions:
    500. Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial. . 2011 Jan; 10(1):209-17. Tsimberidou AM, Takimoto CH, Moulder S, Uehara C, Mita M, Mita A, Urban P, Tan E, Wang Y, Vining D, Kurzrock R. PMID: 21220503.
      View in: PubMed   Mentions:
    501. Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases. Clin Colorectal Cancer. 2010 Dec; 9(5):311-4. Camacho LH, Garcia S, Panchal AM, Lim J, Hong DS, Ng C, Madoff DC, Fu S, Gayed I, Kurzrock R. PMID: 21208846.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    502. Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer. . 2010 Dec; 9(12):3410-9. Tsimberidou AM, Akerley W, Schabel MC, Hong DS, Uehara C, Chhabra A, Warren T, Mather GG, Evans BA, Woodland DP, Swabb EA, Kurzrock R. PMID: 21159616.
      View in: PubMed   Mentions:
    503. Farnesyltransferase inhibitors: where are we now? Expert Opin Investig Drugs. 2010 Dec; 19(12):1569-80. Tsimberidou AM, Chandhasin C, Kurzrock R. PMID: 21083522.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimals
    504. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer. 2011 Apr 15; 117(8):1661-9. Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RC. PMID: 21472713.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCellsCTClinical Trials
    505. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. . 2010 Dec; 9(12):3254-66. Srivastava RK, Kurzrock R, Shankar S. PMID: 21041383.
      View in: PubMed   Mentions:
    506. Development of curcumin as an epigenetic agent. Cancer. 2010 Oct 15; 116(20):4670-6. Fu S, Kurzrock R. PMID: 20597137.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCells
    507. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res. 2010 Dec 01; 16(23):5883-91. Herbst RS, Kurzrock R, Hong DS, Valdivieso M, Hsu CP, Goyal L, Juan G, Hwang YC, Wong S, Hill JS, Friberg G, LoRusso PM. PMID: 20947515.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCTClinical Trials
    508. Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement. Cancer Chemother Pharmacol. 2011 Jul; 68(1):247-53. Tsimberidou AM, Letourneau K, Fu S, Hong D, Naing A, Wheler J, Uehara C, McRae SE, Wen S, Kurzrock R. PMID: 20941597.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    509. Timing of palliative care referral and symptom burden in phase 1 cancer patients: a retrospective cohort study. Cancer. 2010 Sep 15; 116(18):4402-9. Hui D, Parsons H, Nguyen L, Palla SL, Yennurajalingam S, Kurzrock R, Bruera E. PMID: 20564164.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    510. A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors. Invest New Drugs. 2012 Feb; 30(1):327-34. Naing A, Kurzrock R, Adams LM, Kleha JF, Laubscher KH, Bonate PL, Weller S, Fitzgerald C, Xu Y, LoRusso PM. PMID: 20842406.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    511. A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. Cancer. 2010 Sep 01; 116(17):4086-94. Tsimberidou AM, Fu S, Ng C, Lim JA, Wen S, Hong D, Wheler J, Bedikian AY, Eng C, Wallace M, Camacho LH, Kurzrock R. PMID: 20564148.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    512. Phase 1 clinical trials in 83 patients with pancreatic cancer: The M. D. Anderson Cancer Center experience. Cancer. 2011 Jan 01; 117(1):77-85. Vaklavas C, Tsimberidou AM, Wen S, Hong D, Wheler J, Ng CS, Naing A, Uehara C, Wolff RA, Kurzrock R. PMID: 20737567.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    513. Response of histiocytoses to imatinib mesylate: fire to ashes. J Clin Oncol. 2010 Nov 01; 28(31):e633-6. Janku F, Amin HM, Yang D, Garrido-Laguna I, Trent JC, Kurzrock R. PMID: 20733125.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    514. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol. 2010 Aug 10; 28(23):3701-8. van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, Sokol L, Crawford J, Cornfeld M, Qi M, Qin X, Herring J, Casper C, Kurzrock R. PMID: 20625121.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCTClinical Trials
    515. Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors. J Clin Oncol. 2010 Aug 20; 28(24):e415. Subbiah V, Trent JC, Kurzrock R. PMID: 20567010.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    516. Targeted therapy in non-small-cell lung cancer--is it becoming a reality? Nat Rev Clin Oncol. 2010 Jul; 7(7):401-14. Janku F, Stewart DJ, Kurzrock R. PMID: 20551945.
      View in: PubMed   Mentions: 83     Fields:    Translation:Humans
    517. Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment. Clin Cancer Res. 2010 Aug 01; 16(15):4031-7. Garrido-Laguna I, Janku F, Falchook GS, Fu S, Hong DS, Naing A, Aaron J, Wang X, Kies M, Kurzrock R. PMID: 20525754.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    518. Salirasib in the treatment of pancreatic cancer. Future Oncol. 2010 Jun; 6(6):885-91. Bustinza-Linares E, Kurzrock R, Tsimberidou AM. PMID: 20528225.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    519. Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra). . 2010 Jun; 9(6):1485-8. El-Osta H, Janku F, Kurzrock R. PMID: 20501803.
      View in: PubMed   Mentions:
    520. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol. 2010 Jun 10; 28(17):2839-46. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, Ashkenazi A, Jubb AM, Mendelson DS. PMID: 20458040.
      View in: PubMed   Mentions: 140     Fields:    Translation:HumansCTClinical Trials
    521. Equipoise lost: ethics, costs, and the regulation of cancer clinical research. J Clin Oncol. 2010 Jun 10; 28(17):2925-35. Stewart DJ, Whitney SN, Kurzrock R. PMID: 20406924.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    522. A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res. 2010 Apr 15; 16(8):2458-65. Kurzrock R, Patnaik A, Aisner J, Warren T, Leong S, Benjamin R, Eckhardt SG, Eid JE, Greig G, Habben K, McCarthy CD, Gore L. PMID: 20371689.
      View in: PubMed   Mentions: 84     Fields:    Translation:HumansCTClinical Trials
    523. Chemotherapy resistance and retreatment: a dogma revisited. Clin Colorectal Cancer. 2010 Apr; 9(2):E1-4. Naing A, Kurzrock R. PMID: 20378496.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    524. Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience. Gynecol Oncol. 2010 Jun; 117(3):467-72. Moroney J, Wheler J, Hong D, Naing A, Falchook G, Bodurka D, Coleman R, Lu K, Xiao L, Kurzrock R. PMID: 20347123.
      View in: PubMed   Mentions: 9